GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE

POCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION

A Guide for Health Care Professionals

2022 EDITION

© 2021 Global Initiative for Chronic Obstructive Lung Disease, Inc.
TABLE OF CONTENTS

TABLE OF CONTENTS ................................................................. iii
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND
PREVENTION OF COPD ............................................................ 1
INTRODUCTION ........................................................................ 1
DEFINITION AND OVERVIEW .................................................... 1
WHAT IS CHRONIC OBSTRUCTIVE PULMONARY DISEASE
(COPD)? ............................................................................. 1
WHAT CAUSES COPD? ......................................................... 2
DIAGNOSIS AND ASSESSMENT OF COPD ................................. 3
OVERALL KEY POINTS: .......................................................... 3
DIAGNOSIS .............................................................................. 4
DIFFERENTIAL DIAGNOSIS ...................................................... 4
ASSESSMENT ........................................................................... 7
Classification of severity of airflow limitation ............................ 7
Assessment of symptoms .......................................................... 7
Combined COPD assessment ........................................................ 8
EVIDENCE SUPPORTING PREVENTION AND MAINTENANCE
THERAPY ............................................................................... 11
OVERALL KEY POINTS: .......................................................... 11
SMOKING CESSATION ............................................................. 12
VACCINATIONS ........................................................................ 12
PHARMACOLOGICAL THERAPY FOR STABLE COPD ................. 14
Overview of the medications ...................................................... 14
Bronchodilators ....................................................................... 14
Antimuscarinic drugs ............................................................... 15
Methylxanthines ...................................................................... 15
Combination bronchodilator therapy .......................................... 15
Anti-inflammatory agents ......................................................... 17
Inhaled corticosteroids (ICS) ..................................................... 17
Triple therapy (LABA/LAMA/ICS) .............................................. 21
Oral glucocorticoids ............................................................... 21
Phosphodiesterase-4 (PDE4) inhibitors ...................................... 21
Antibiotics .............................................................................. 22
Mucolytic (mucokinetics, mucoregulators) and antioxidant
agents (NAC, carbocysteine, erdosteine) ................................... 22
Other drugs with potential to reduce exacerbations............... 22
Other pharmacological treatments ........................................... 23
REHABILITATION, EDUCATION & SELF-MANAGEMENT .... 23
Pulmonary rehabilitation ......................................................... 23
SUPPORTIVE, PALLIATIVE, END-OF-LIFE & HOSPICE CARE ... 24
Symptom control and palliative care ........................................ 24
OTHER TREATMENTS ............................................................. 25
INTERVENTIONAL THERAPY ....................................................... 25
Surgical Interventions .............................................................. 25
Bronchoscopic interventions to reduce hyperinflation in
severe emphysema ................................................................. 26
MANAGEMENT OF STABLE COPD ............................................. 26
OVERALL KEY POINTS: .......................................................... 26
IDENTIFY AND REDUCE EXPOSURE TO RISK FACTORS ........ 27
TREATMENT OF STABLE COPD: PHARMACOLOGICAL
TREATMENT ........................................................................ 28
Algorithms for the assessment, initiation and follow-up
management of pharmacological treatment ......................... 29
TREATMENT OF STABLE COPD: NON-PHARMACOLOGICAL
TREATMENT ..................................................................... 34
Oxygen therapy ..................................................................... 36
MONITORING AND FOLLOW-UP ............................................. 38
MANAGEMENT OF EXACERBATIONS ...................................... 38
OVERALL KEY POINTS: .......................................................... 38
TREATMENT OPTIONS ............................................................ 39
Treatment setting ................................................................. 39
Respiratory support ............................................................... 41
Hospital discharge and follow-up ........................................... 42
Prevention of exacerbations .................................................... 44
COPD AND COMORBIDITIES .................................................. 45
OVERALL KEY POINTS: .......................................................... 45
COVID-19 AND COPD ............................................................ 45
OVERALL KEY POINTS: .......................................................... 45
REMOTE COPD PATIENT FOLLOW-UP DURING COVID-19
PANDEMIC RESTRICTIONS .................................................... 48
REFERENCES .......................................................................... 48
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF COPD

INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) is now one of the top three causes of death worldwide and 90% of these deaths occur in low- and middle-income countries (LMICs). More than 3 million people died of COPD in 2012 accounting for 6% of all deaths globally. COPD represents an important public health challenge that is both preventable and treatable. COPD is a major cause of chronic morbidity and mortality throughout the world; many people suffer from this disease for years and die prematurely from it or its complications. Globally, the COPD burden is projected to increase in coming decades because of continued exposure to COPD risk factors and aging of the population.

This Pocket Guide has been developed from the Global Strategy for the Diagnosis, Management, and Prevention of COPD (2022 Report), which aims to provide a non-biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD that can aid the clinician. Discussions of COPD and COPD management, evidence levels, and specific citations from the scientific literature are included in that source document, which is available from www.goldcopd.org.

DEFINITION AND OVERVIEW

OVERALL KEY POINTS:

- Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

- The most common respiratory symptoms include dyspnea, cough and/or sputum production. These symptoms may be under-reported by patients.

- The main risk factor for COPD is tobacco smoking but other environmental exposures such as biomass fuel exposure and air pollution may contribute. Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development and accelerated aging.

- COPD may be punctuated by periods of acute worsening of respiratory symptoms, called exacerbations.

- In most patients, COPD is associated with significant concomitant chronic diseases, which increase its morbidity and mortality.

WHAT IS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)?

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases and influenced by host factors including abnormal lung development. Significant comorbidities may have an impact on morbidity and mortality. There may be significant lung pathology (e.g., emphysema) in the absence of airflow limitation that needs further evaluation.
WHAT CAUSES COPD?

Worldwide, the most commonly encountered risk factor for COPD is tobacco smoking. Non-smokers may also develop COPD, and COPD is the result of a complex interplay of long-term cumulative exposure to noxious gases and particles, combined with a variety of host factors including genetics, airway hyper-responsiveness and poor lung growth during childhood. The risk of developing COPD is related to the following factors:

- **Tobacco smoke.** Cigarette smokers have a higher prevalence of respiratory symptoms and lung function abnormalities, a greater annual rate of decline in FEV₁, and a greater COPD mortality rate than non-smokers. Other types of tobacco (e.g., pipe, cigar, water pipe) and marijuana are also risk factors for COPD, as well as environmental tobacco smoke (ETS).

- **Indoor air pollution.** Indoor air pollution resulting from the burning of wood and other biomass fuels used for cooking and heating in poorly vented dwellings, is a risk factor that particularly affects women in developing countries. There is a lack of research about biomass related COPD, although there is limited evidence from an observational study that switching to cleaner cooking fuels or reducing exposure may reduce COPD risk in non-smokers.

- **Occupational exposures.** Occupational exposures including organic and inorganic dusts, chemical agents and fumes, are under-appreciated risk factors for COPD. Individuals with exposure to inhalation of high doses of pesticides have a higher incidence of respiratory symptoms, airways obstruction and COPD.

- **Outdoor air pollution.** Outdoor air pollution also contributes to the lungs’ total burden of inhaled particles, although it appears to have a relatively small effect in causing COPD. There is a significant association between ambient levels of particulate matter and incidence of COPD.

- **Genetic factors.** Genetic factors such as severe hereditary deficiency of alpha-1 antitrypsin (AATD); the gene encoding matrix metalloproteinase 12 (MMP-12) and glutathione S-transferase have also been related to a decline in lung function or risk of COPD.

- **Age and sex.** Aging and female sex increase COPD risk.

- **Lung growth and development.** Any factor that affects lung growth during gestation and childhood (low birth weight, respiratory infections, etc.) has the potential to increase an individual’s risk of developing COPD.

- **Socioeconomic status.** Poverty is consistently associated with airflow obstruction and lower socioeconomic status is associated with an increased risk of developing COPD. It is not clear, however, whether this pattern reflects exposures to indoor and outdoor air pollutants, crowding, poor nutrition, infections, or other factors related to low socioeconomic status.

- **Asthma and airway hyper-reactivity.** Asthma may be a risk factor for the development of airflow limitation and COPD.

- **Chronic bronchitis.** Chronic bronchitis may increase the frequency of total and severe exacerbations.

- **Infections.** A history of severe childhood respiratory infection has been associated with reduced lung function and increased respiratory symptoms in adulthood.
OVERALL KEY POINTS:

- **COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, a history of recurrent lower respiratory tract infections and/or a history of exposure to risk factors for the disease.**

- **Spirometry is required to make the diagnosis; the presence of a post-bronchodilator FEV₁/FVC < 0.70 confirms the presence of persistent airflow limitation.**

- **The goals of COPD assessment are to determine the level of airflow limitation, the impact of disease on the patient’s health status, and the risk of future events (such as exacerbations, hospital admissions, or death), in order to guide therapy.**

- **Concomitant chronic diseases occur frequently in COPD patients, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, anxiety, and lung cancer. These comorbidities should be actively sought and treated appropriately when present as they can influence mortality and hospitalizations independently.**

---

**KEY INDICATORS FOR CONSIDERING A DIAGNOSIS OF COPD**

Consider COPD, and perform spirometry, if any of these indicators are present in an individual over age 40. These indicators are not diagnostic themselves, but the presence of multiple key indicators increases the probability of a diagnosis of COPD. Spirometry is required to establish a diagnosis of COPD.

<table>
<thead>
<tr>
<th>Dyspnea that is:</th>
<th>Progressive over time.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Characteristically worse with exercise.</td>
</tr>
<tr>
<td></td>
<td>Persistent.</td>
</tr>
<tr>
<td>Chronic Cough:</td>
<td>May be intermittent and may be unproductive.</td>
</tr>
<tr>
<td></td>
<td>Recurrent wheeze.</td>
</tr>
<tr>
<td>Chronic Sputum Production</td>
<td>Any pattern of chronic sputum production may indicate COPD.</td>
</tr>
<tr>
<td>Recurrent Lower Respiratory Tract Infections</td>
<td></td>
</tr>
<tr>
<td>History of Risk Factors:</td>
<td>Host factors (such as genetic factors, congenital/developmental abnormalities etc.).</td>
</tr>
<tr>
<td></td>
<td>Tobacco smoke (including popular local preparations).</td>
</tr>
<tr>
<td></td>
<td>Smoke from home cooking and heating fuels.</td>
</tr>
<tr>
<td></td>
<td>Occupational dusts, vapors, fumes, gases and other chemicals.</td>
</tr>
<tr>
<td>Family History of COPD and/or Childhood Factors:</td>
<td>For example low birthweight, childhood respiratory infections etc.</td>
</tr>
</tbody>
</table>
DIAGNOSIS

COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease (see Table). Spirometry is required to make the diagnosis in this clinical context, the presence of a post-bronchodilator FEV₁/FVC < 0.70 confirms the presence of persistent airflow limitation and thus of COPD in patients with appropriate symptoms and significant exposures to noxious stimuli. Spirometry is the most reproducible and objective measurement of airflow limitation. It is a noninvasive and readily available test. Despite its good sensitivity, peak expiratory flow measurement alone cannot be reliably used as the only diagnostic test because of its weak specificity. The WHO has defined a minimum set of interventions for the diagnosis of COPD in primary care.

DIFFERENTIAL DIAGNOSIS

A major differential diagnosis is asthma. In some patients with chronic asthma, a clear distinction from COPD is not possible using current imaging and physiological testing techniques. In these patients, current management is similar to that of asthma. Other potential diagnoses are usually easier to distinguish from COPD (see Table).

Alpha-1 antitrypsin deficiency (AATD) screening. The World Health Organization recommends that all patients with a diagnosis of COPD should be screened once especially in areas with high AATD prevalence. A low concentration (< 20% normal) is highly suggestive of homozygous deficiency. Family members should also be screened.

Additional investigations

The following additional investigations may be considered as part of the diagnosis and assessment of COPD.

Imaging. A chest X-ray is not useful to establish a diagnosis in COPD, but it is valuable in excluding alternative diagnoses and establishing the presence of significant comorbidities such as concomitant respiratory (pulmonary fibrosis, bronchiectasis, pleural diseases), skeletal (e.g., kyphoscoliosis), and cardiac diseases (e.g., cardiomegaly). Radiological changes associated with COPD include signs of lung hyperinflation (flattened diaphragm and an increase in the volume of the retrosternal air space), hyperlucency of the lungs, and rapid tapering of the vascular markings. Computed tomography (CT) of the chest is not routinely recommended except for detection of bronchiectasis and COPD patients that meet the criteria for lung cancer risk assessment. The presence of emphysema in particular may increase the risk for development of lung cancer. However, CT scanning may be helpful in the differential diagnosis where concomitant diseases are present. In addition, if a surgical procedure such as lung volume reduction or increasingly non-surgical based lung volume reduction is contemplated, a chest CT scan is necessary since the distribution of emphysema is one of the most important determinants of surgical suitability. A CT scan is also required for patients being evaluated for lung transplantation.

Lung volumes. COPD patients exhibit gas trapping (a rise in residual volume) from the early stages of the disease, and as airflow limitation worsens, static hyperinflation (an increase in total lung capacity) occurs. These changes can be documented by body plethysmography, or less accurately by helium dilution lung volume measurement. These measurements help characterize the severity of COPD but are not essential to patient management.

Diffusing capacity of the lungs for carbon monoxide (DLco). The introduction into clinical practice of the single breath holding technique for DLco provided a useful clinical tool to evaluate the gas transfer properties of the respiratory system. Although well-standardized and with valid predicted values of practical utility, its use has been limited to being a test conducted primarily in the pulmonary function laboratories. The advent of reliable portable systems capable of providing accurate determinations in the field, expands its potential use as a complement to the information provided by simple spirometry. In patients with COPD, cross-sectionally obtained low values of DLco (<
60% predicted) are associated with: decreased exercise capacity; increased symptoms; worse health status\textsuperscript{43-45}; and increased risk of death, independent of other clinical variables and the degree of airflow limitation.\textsuperscript{46-48} Additionally, in COPD patients, low DLco values help preclude surgical lung resection in patients with cancer\textsuperscript{49} while in smokers without airflow limitation, values < 80% predicted (as a marker of emphysema) signal an increased risk for developing COPD over time.\textsuperscript{50} Over time patients with COPD have an accelerated decline in DLco compared to smokers without the disease, and this decline is significantly greater in women than men.\textsuperscript{51,52} However, the DLco decline is slow, and years of follow up are often needed before a meaningful change in DLco is detected. A DLco measurement should be performed in every patient with COPD with symptoms (dyspnea) disproportionate to the degree of airflow obstruction.

**Oximetry and arterial blood gas measurement.** Pulse oximetry can be used to evaluate a patient’s arterial oxygen saturation and need for supplemental oxygen therapy. Pulse oximetry should be used to assess all patients with clinical signs suggestive of respiratory failure or right heart failure. If peripheral arterial oxygen saturation is < 92% arterial or capillary blood gases should be assessed.\textsuperscript{53,54}

**Exercise testing and assessment of physical activity.** Objectively measured exercise impairment, assessed by a reduction in self-paced walking distance\textsuperscript{55,56} or during incremental exercise testing in a laboratory,\textsuperscript{57} is a powerful indicator of health status impairment and predictor of prognosis; exercise capacity may fall in the year before death.\textsuperscript{58} Walking tests can be useful for assessing disability and risk of mortality\textsuperscript{59} and are used to assess the effectiveness of pulmonary rehabilitation. Both the paced shuttle walk test\textsuperscript{60} and the unpaced 6-minute walk test can be used.\textsuperscript{61,62} As the course length has a substantial impact on the distance walked, existing reference equations established for a 30 meter course cannot be applied to predict the distance achieved on shorter courses.\textsuperscript{63} Laboratory testing using cycle or treadmill ergometry can assist in identifying co-existing or alternative conditions e.g., cardiac diagnoses.

Monitoring of physical activity may be more relevant regarding prognosis than evaluating only exercise capacity.\textsuperscript{64} This can be conducted using accelerometers or multi-sensor instruments.

**Composite scores.** Several variables identify patients at increased risk for mortality including FEV\textsubscript{1}, exercise tolerance assessed by walking distance or peak oxygen consumption, weight loss, and reduction in arterial oxygen tension. A relatively simple approach to identifying disease severity using a combination of most of the above variables has been proposed. The BODE (Body mass index, Obstruction, Dyspnea, and Exercise) method gives a composite score that is a better predictor of subsequent survival than any single component.\textsuperscript{65,66} Simpler alternatives that do not include an exercise test have been suggested but all these approaches need validation across a wide range of disease severities and clinical settings to confirm that they are suitable for routine clinical use.\textsuperscript{67,68}

**Differential diagnoses.** In some patients with chronic asthma, a clear distinction from COPD is difficult using current imaging and physiological testing techniques, since the two conditions share common traits and clinical expressions. Most other potential differential diagnoses are easier to distinguish from COPD (see Table).
Biomarkers. There is rapidly increasing interest in the use of biomarkers in COPD. Biomarkers are ‘characteristics that are objectively measured and evaluated as an indicator of normal biological or pathogenic processes or pharmacological responses to therapeutic interventions’. In general such data has proven difficult to interpret, largely as a result of weak associations and lack of reproducibility between large patient cohorts which was further confirmed in the recent SUMMIT study. Some studies have indicated the use of C-reactive protein (CRP) and procalcitonin in restricting antibiotic usage during exacerbations, although the observed sputum color remains highly sensitive and specific for a high bacterial load during such episodes.

At present the assessment of blood eosinophils provides the best guidance to the use of inhaled corticosteroids (ICS) especially in the prevention of some exacerbations. Continued cautious and realistic interpretation of the role of biomarkers in the management of identified clinical traits is required.
Other considerations. It is clear that some patients without evidence of airflow limitation have evidence of structural lung disease on chest imaging (emphysema, gas trapping, airway wall thickening) that is consistent with what is found in patients with COPD. Such patients may report exacerbations of respiratory symptoms or even require treatment with respiratory medications on a chronic basis. Whether these patients have acute or chronic bronchitis, a persistent form of asthma or an earlier presentation of what will become COPD as it is currently defined, is unclear at present and will require further study.

ASSESSMENT

The goals of COPD assessment are to determine the level of airflow limitation, its impact on the patient's health status and the risk of future events (such as exacerbations, hospital admissions or death), in order to, eventually, guide therapy. To achieve these goals, COPD assessment must consider the following aspects of the disease separately:

► The presence and severity of the spirometric abnormality
► Current nature and magnitude of the patient’s symptoms
► History of moderate and severe exacerbations
► Presence of comorbidities

Classification of severity of airflow limitation

The classification of airflow limitation severity in COPD (see Table) uses specific spirometric cut-points for purposes of simplicity. Spirometry should be performed after the administration of an adequate dose of at least one short-acting inhaled bronchodilator in order to minimize variability.

It should be noted that there is only a weak correlation between FEV₁, symptoms and impairment of a patient’s health status. For this reason, formal symptomatic assessment is required.

<table>
<thead>
<tr>
<th>CLASSIFICATION OF AIRFLOW LIMITATION SEVERITY IN COPD (BASED ON POST-BRONCHODILATOR FEV₁)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In patients with FEV₁/FVC &lt; 0.70:</strong></td>
</tr>
<tr>
<td><strong>GOLD 1:</strong> Mild</td>
</tr>
<tr>
<td>FEV₁ ≥ 80% predicted</td>
</tr>
<tr>
<td><strong>GOLD 2:</strong> Moderate</td>
</tr>
<tr>
<td>50% ≤ FEV₁ &lt; 80% predicted</td>
</tr>
<tr>
<td><strong>GOLD 3:</strong> Severe</td>
</tr>
<tr>
<td>30% ≤ FEV₁ &lt; 50% predicted</td>
</tr>
<tr>
<td><strong>GOLD 4:</strong> Very Severe</td>
</tr>
<tr>
<td>FEV₁ &lt; 30% predicted</td>
</tr>
</tbody>
</table>

Assessment of symptoms

In the past, COPD was viewed as a disease largely characterized by breathlessness. A simple measure of breathlessness such as the Modified British Medical Research Council (mMRC) Questionnaire (see Table) was considered adequate for assessment of symptoms, as the mMRC relates well to other measures of health status and predicts future mortality risk. However, it is now recognized that COPD impacts patients beyond just dyspnea. For this reason, a comprehensive assessment of symptoms is recommended using measures such as the COPD Assessment Test (CAT™) (see Figure) and The COPD Control Questionnaire (The CCQ©).
Combined COPD assessment

An understanding of the impact of COPD on an individual patient combines the symptomatic assessment with the patient’s spirometric classification and/or risk of exacerbations. The “ABCD” assessment tool of the 2011 GOLD update was a major step forward from the simple spirometric grading system of the earlier versions of GOLD because it incorporated patient-reported outcomes and highlighted the importance of exacerbation prevention in the management of COPD. However, there were some important limitations. Firstly, the ABCD assessment tool performed no better than the spirometric grades for mortality prediction or other important health outcomes in COPD. Moreover, group “D” outcomes were modified by two parameters: lung function and/or exacerbation history, which caused confusion. To address these and other concerns (while at the same time maintaining consistency and simplicity for the practicing clinician), a refinement of the ABCD assessment tool is proposed that separates spirometric grades from the “ABCD” groups. For some therapeutic recommendations, ABCD groups are derived exclusively from patient symptoms and their history of exacerbation. Spirometry, in conjunction with patient symptoms and history of moderate and severe exacerbations, remains vital for the diagnosis, prognostication and consideration of other important therapeutic approaches. This new approach to assessment is illustrated in the Figure.

In the revised assessment scheme, patients should undergo spirometry to determine the severity of airflow limitation (i.e., spirometric grade). They should also undergo assessment of either dyspnea using mMRC or symptoms using CAT™. Finally, their history of moderate and severe exacerbations (including prior hospitalizations) should be recorded.
The number provides information regarding severity of airflow limitation (spirometric grade 1 to 4) while the letter (groups A to D) provides information regarding symptom burden and risk of exacerbation which can be used to guide therapy. FEV₁ is a very important parameter at the population-level in the prediction of important clinical outcomes such as mortality and hospitalizations or prompting consideration for non-pharmacological therapies such as lung volume reduction or lung transplantation. However, it is important to note that at the individual patient level, FEV₁ loses precision and thus cannot be used alone to determine all therapeutic options. Furthermore, in some circumstances, such as during hospitalization or urgent presentation to the clinic or emergency room, the ability to assess patients based on symptoms and exacerbation history, independent of the spirometric value, allows clinicians to initiate a treatment plan based on the revised ABCD scheme alone. This assessment approach acknowledges the limitations of FEV₁ in making treatment decisions for individualized patient care and highlights the importance of patient symptoms and exacerbation risks in guiding therapies in COPD. The separation of airflow limitation from clinical parameters makes it clearer what is being evaluated and ranked. This facilitates more precise treatment recommendations based on parameters that are driving the patient’s symptoms at any given time.
Example: Consider two patients - both patients with FEV₁ < 30% of predicted, CAT™ scores of 18 and one with no exacerbations in the past year and the other with three moderate exacerbations in the past year. Both would have been labelled GOLD D in the prior classification scheme. However, with the new proposed scheme, the subject with three moderate exacerbations in the past year would be labelled GOLD grade 4, group D.
OVERALL KEY POINTS:

• Smoking cessation is key. Pharmacotherapy and nicotine replacement reliably increase long-term smoking abstinence rates. Legislative smoking bans and counseling, delivered by healthcare professionals, improve quit rates.

• The effectiveness and safety of e-cigarettes as a smoking cessation aid is uncertain at present.

• Pharmacological therapy can reduce COPD symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance. Data suggest beneficial effects on rates of lung function decline and mortality.

• Each pharmacological treatment regimen should be individualized and guided by the severity of symptoms, risk of exacerbations, side-effects, comorbidities, drug availability and cost, and the patient’s response, preference and ability to use various drug delivery devices.

• Inhaler technique needs to be assessed regularly.

• COVID-19 vaccines are highly effective against SARS-CoV-2 infection and people with COPD should have the COVID-19 vaccination in line with national recommendations.

• Influenza vaccination decreases the incidence of lower respiratory tract infections.

• Pneumococcal vaccination decreases lower respiratory tract infections.

• CDC recommends the Tdap vaccination (dT&ap;/dTpa) in COPD patients to protect against pertussis, tetanus and diphtheria, in those who were not vaccinated in adolescence and Zoster vaccine to protect against shingles for adults with COPD aged ≥ 50 years.

• Pulmonary rehabilitation with its core components, including exercise training combined with disease-specific education, improves exercise capacity, symptoms and quality of life across all grades of COPD severity.

• In patients with severe resting chronic hypoxemia, long-term oxygen therapy improves survival.

• In patients with stable COPD and resting or exercise-induced moderate desaturation, long-term oxygen treatment should not be prescribed routinely. However, individual patient factors must be considered when evaluating the patient’s need for supplemental oxygen.

• In patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory failure, long-term non-invasive ventilation may decrease mortality and prevent re-hospitalization.

• In select patients with advanced emphysema refractory to optimized medical care, surgical or bronchoscopic interventional treatments may be beneficial.

• Palliative approaches are effective in controlling symptoms in advanced COPD.
**SMOKING CESSATION**

A significant proportion of COPD patients continue to smoke despite knowing they have the disease (approximately 40% of COPD patients are current smokers), and this behavior has a negative impact on prognosis and progression of the disease.\(^7\) Smoking cessation has the greatest capacity to influence the natural history of COPD. If effective resources and time are dedicated to smoking cessation, long-term quit success rates of up to 25% can be achieved.\(^8\) Besides individual approaches to smoking cessation, legislative smoking bans are effective in increasing quit rates and reducing harm from second-hand smoke exposure.\(^9\) A five-step program for intervention (see Table)\(^86\) provides a helpful strategic framework.\(^86,88,89\)

---

**VACCINATIONS**

**VACCINATION FOR STABLE COPD**

- Influenza vaccination reduces serious illness and death in COPD patients (Evidence B).
- The WHO and CDC recommend SARS-Cov-2 (COVID-19) vaccination for people with COPD (Evidence B).
- The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been shown to reduce the incidence of community-acquired pneumonia in COPD patients aged < 65 years with an FEV\(_1\) < 40% predicted and in those with comorbidities (Evidence B).
- In the general population of adults ≥ 65 years the 13-valent conjugated pneumococcal vaccine (PCV13) has demonstrated significant efficacy in reducing bacteremia & serious invasive pneumococcal disease (Evidence B).
- The CDC recommends Tdap (dTdap/dTpa) vaccination to protect against pertussis (whooping cough) for adults with COPD who were not vaccinated in adolescence (Evidence B) and Zoster vaccine to protect against shingles for adults with COPD aged ≥ 50 years (Evidence B).
<table>
<thead>
<tr>
<th>Generic Drug Name</th>
<th>Inhaler Type</th>
<th>Nebulizer</th>
<th>Oral</th>
<th>Injection</th>
<th>Duration Of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BETA&lt;sub&gt;2&lt;/sub&gt;-AGONISTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenoterol</td>
<td>MDI</td>
<td>✓</td>
<td>pill, syrup</td>
<td></td>
<td>4-6 hours</td>
</tr>
<tr>
<td>Levalbuterol</td>
<td>MDI</td>
<td>✓</td>
<td></td>
<td></td>
<td>6-8 hours</td>
</tr>
<tr>
<td>Salbutamol (albuterol)</td>
<td>MDI &amp; DPI</td>
<td>✓</td>
<td>pill, syrup,</td>
<td>✓</td>
<td>12 hours (ext. release)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>extended release tablet</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Terbutaline</td>
<td>DPI</td>
<td></td>
<td></td>
<td>✓</td>
<td>4-6-6 hours</td>
</tr>
<tr>
<td><strong>LONG-ACTING (LABA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arformoterol</td>
<td>DPI</td>
<td></td>
<td></td>
<td>✓</td>
<td>12 hours</td>
</tr>
<tr>
<td>Formoterol</td>
<td>DPI</td>
<td></td>
<td></td>
<td>✓</td>
<td>12 hours</td>
</tr>
<tr>
<td>Indacaterol</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td>Olopatadine</td>
<td>SMI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td>Salmeterol</td>
<td>MDI &amp; DPI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td><strong>ANTICHOLINERGICS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SHORT-ACTING (SAMA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipratropium bromide</td>
<td>MDI</td>
<td>✓</td>
<td></td>
<td></td>
<td>6-8 hours</td>
</tr>
<tr>
<td>Oxitropium bromide</td>
<td>MDI</td>
<td></td>
<td></td>
<td></td>
<td>7-9 hours</td>
</tr>
<tr>
<td><strong>LONG-ACTING (LAMA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acildinium bromide</td>
<td>DPI, MDI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Glycopyrronium bromide</td>
<td>DPI</td>
<td></td>
<td>solution</td>
<td>✓</td>
<td>12-24 hours</td>
</tr>
<tr>
<td>Tiotropium</td>
<td>DPI, SMI, MDI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td>Umeclidinium</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td>Glycopyrrolate</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Relefenac</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td><strong>COMBINATION SHORT-ACTING BETA&lt;sub&gt;2&lt;/sub&gt;-AGONIST PLUS ANTICHOLINERGIC IN ONE DEVICE (SABA/SAMA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenoterol/ipratropium</td>
<td>SMI</td>
<td>✓</td>
<td></td>
<td></td>
<td>6-8 hours</td>
</tr>
<tr>
<td>Salbutamol/ipratropium</td>
<td>SMI, MDI</td>
<td>✓</td>
<td></td>
<td></td>
<td>6-8 hours</td>
</tr>
<tr>
<td><strong>COMBINATION LONG-ACTING BETA&lt;sub&gt;2&lt;/sub&gt;-AGONIST PLUS ANTICHOLINERGIC IN ONE DEVICE (LABA/LAMA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/acildinium</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Formoterol/glycopyrronium</td>
<td>MDI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Indacaterol/glycopyrronium</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>12-24 hours</td>
</tr>
<tr>
<td>Vilaroterol/umeclidinium</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td>Olopatadine/tiotropium</td>
<td>SMI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td><strong>METHYLPXANTHINES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aminophylline</td>
<td>solution</td>
<td>✓</td>
<td>Variable, up to 24 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Theophylline (SR)</td>
<td>pill</td>
<td>✓</td>
<td>Variable, up to 24 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COMBINATION OF LONG-ACTING BETA&lt;sub&gt;2&lt;/sub&gt;-AGONIST PLUS CORTICOSTEROID IN ONE DEVICE (LABA/ICS)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/beclometasone</td>
<td>MDI, DPI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Formoterol/budesonide</td>
<td>MDI, DPI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Formoterol/mometasone</td>
<td>MDI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Salmeterol/fluticasone propionate</td>
<td>MDI, DPI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Vilaroterol/fluticasone furate</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td><strong>TRIPLE COMBINATION IN ONE DEVICE (LABA/LAMA/ICS)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluticasone/umeclidinium/vilaroter</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td>Budesonide/formoterol/glycopyrronium</td>
<td>MDI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Budesonide/formoterol/glycopyrronate</td>
<td>MDI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td><strong>PHOSPHODIESTERASE-4 INHIBITORS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roflumilast</td>
<td>pill</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td><strong>MUCOLYTIC AGENTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erdosteine</td>
<td>pill</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Carbocysteine†</td>
<td>pill</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-acetylcysteine†</td>
<td>pill</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Not all formulations are available in all countries. In some countries other formulations and dosages may be available. † Dosing regimens are under discussion. MDI = metered dose inhaler; DPI = dry powder inhaler; SMI = soft mist inhaler. Note that glycopyrrlate & glycopyrronium are the same compound.
PHARMACOLOGICAL THERAPY FOR STABLE COPD

Overview of the medications
Pharmacological therapy for COPD is used to reduce symptoms, reduce the frequency and severity of exacerbations, and improve exercise tolerance and health status. Individual clinical trials have not been sufficiently conclusive to show that pharmacotherapy can reduce the rate of FEV₁ decline. However, a systematic review combining data from 9 studies demonstrated a reduction in the rate of FEV₁ decline of 5.0 mL/year in active treatment arms compared with placebo arms. The difference between long-acting bronchodilator containing treatment arms and placebo arms was 4.9 mL/year. The difference between inhaled corticosteroid containing treatment arms and placebo arms was 7.3 mL/year. Although we need to be aware of the potential benefit of pharmacotherapy in reducing the rate of lung function decline, further research is needed to know which patients are likely to benefit.

The classes of medications commonly used to treat COPD are shown in Table 3.3. The choice within each class depends on the availability and cost of medication and favorable clinical response balanced against side effects. Each treatment regimen needs to be individualized as the relationship between severity of symptoms, airflow limitation, and severity of exacerbations can differ between patients. The WHO has defined a minimum set of interventions for the management of stable COPD in primary care.

Bronchodilators
Bronchodilators are medications that increase FEV₁ and/or change other spirometric variables.

► Bronchodilator medications in COPD are most often given on a regular basis to prevent or reduce symptoms.
► Toxicity is also dose-related.
► Use of short acting bronchodilators on a regular basis is not generally recommended.

Beta₂-agonists
► The principal action of beta₂-agonists is to relax airway smooth muscle by stimulating beta₂-adrenergic receptors, which increases cyclic AMP and produces functional antagonism to bronchoconstriction.
► There are short-acting (SABA) and long-acting (LABA) beta₂-agonists. The effect of SABAs usually wears off within 4 to 6 hours. Regular and as-needed use of SABAs improve FEV₁ and symptoms.
► For single-dose, as-needed use in COPD, there appears to be no advantage in routinely using levalbuterol over conventional bronchodilators. LABAs show duration of action of 12 or more hours and do not preclude additional benefit from as-needed SABA therapy.
► Formoterol and salmeterol are twice-daily LABAs that significantly improve FEV₁ and lung volumes, dyspnea, health status, exacerbation rate and number of hospitalizations, but have no effect on mortality or rate of decline of lung function.
► Indacaterol is a once daily LABA that improves breathlessness, health status and exacerbation rate. Some patients experience cough following the inhalation of indacaterol.
► Oladaterol and vilanterol are additional once daily LABAs that improve lung function and symptoms.

Adverse effects. Stimulation of beta₂-adrenergic receptors can produce resting sinus tachycardia and has the potential to precipitate cardiac rhythm disturbances in susceptible patients. Exaggerated somatic tremor is troublesome in some older patients treated with higher doses of beta₂-agonists, regardless of route of administration. Although hypokalemia can occur, especially when treatment is combined with thiazide diuretics, and oxygen consumption can be increased under resting conditions in patients with chronic heart failure, these metabolic effects decrease over time (i.e., show tachyphylaxis). Mild falls in partial pressure of oxygen (PaO₂) can occur after administration of both SABAs and LABAs but the clinical significance of these changes is uncertain. Despite prior concerns related to the use of beta₂-agonists in the management of asthma, no association between beta₂-agonist use and loss of lung function or increased mortality has been reported in COPD.
Antimuscarinic drugs

► Antimuscarinic drugs block the bronchoconstrictor effects of acetylcholine on M3 muscarinic receptors expressed in airway smooth muscle.\textsuperscript{111}

► Short-acting antimuscarinics (SAMAs), namely ipratropium and oxtropium, also block the inhibitory neuronal receptor M2, which potentially can cause vagally induced bronchoconstriction.\textsuperscript{112}

► Long-acting antimuscarinic antagonists (LAMAs), such as tiotropium, aclidinium, glycopyrronium bromide (also known as glycopyrrolate) and umeclidinium have prolonged binding to M3 muscarinic receptors, with faster dissociation from M2 muscarinic receptors, thus prolonging the duration of bronchodilator effect.\textsuperscript{111}

► A systematic review of randomized controlled trials concluded that ipratropium, a short acting muscarinic antagonist, alone provided small benefits over short-acting beta\textsubscript{2}-agonist in terms of lung function, health status and requirement for oral steroids.\textsuperscript{113}

► LAMA treatments (tiotropium) improve symptoms and health status.\textsuperscript{111,114} They also improve the effectiveness of pulmonary rehabilitation\textsuperscript{115,116} and reduce exacerbations and related hospitalizations.\textsuperscript{114}

► Clinical trials have shown a greater effect on exacerbation rates for LAMA treatment (tiotropium) versus LABA treatment.\textsuperscript{117,118}

Adverse effects. Inhaled anticholinergic drugs are poorly absorbed which limits the troublesome systemic effects observed with atropine.\textsuperscript{111,119} Extensive use of this class of agents in a wide range of doses and clinical settings has shown them to be very safe. The main side effect is dryness of mouth.\textsuperscript{112,120} Although occasional urinary symptoms have been reported, there are no data to prove a true causal relationship.\textsuperscript{121} Some patients using ipratropium report a bitter, metallic taste. An unexpected small increase in cardiovascular events in COPD patients regularly treated with ipratropium bromide has been reported.\textsuperscript{122,123} In a large, long-term clinical trial in COPD patients, tiotropium added to other standard therapies had no effect on cardiovascular risk.\textsuperscript{94} Although there were some initial concerns regarding the safety of tiotropium delivery via the Respimat\textsuperscript{®} inhaler, the findings of a large trial observed no difference in mortality or exacerbation delivery when comparing tiotropium in a dry-powder inhaler and the Respimat\textsuperscript{®} inhaler.\textsuperscript{125}

Methylxanthines

► Controversy remains about the exact effects of xanthine derivatives.

► Theophylline, the most commonly used methylxanthine, is metabolized by cytochrome P450 mixed function oxidases. Clearance of the drug declines with age.

► There is evidence for a modest bronchodilator effect compared with placebo in stable COPD.\textsuperscript{126}

► Addition of theophylline to salmeterol produces a greater improvement in FEV\textsubscript{1} and breathlessness than salmeterol alone.\textsuperscript{127,128}

► Earlier studies reported contradictory evidence regarding the effect of low-dose theophylline on exacerbation rates.\textsuperscript{129,130}

► A large placebo-controlled trial showed no effect of oral theophylline alone or in combination with prednisolone 5 mg daily on exacerbations of severe COPD.\textsuperscript{131}

Adverse effects. Toxicity is dose-related, which is a particular problem with xanthine derivatives because their therapeutic ratio is small and most of the benefit occurs only when near-toxic doses are given.\textsuperscript{126,132}

Combination bronchodilator therapy

Combining bronchodilators with different mechanisms and durations of action may increase the degree of bronchodilation with a lower risk of side-effects compared to increasing the dose of a single bronchodilator.\textsuperscript{133,134} Combinations of SABAs and SAMAs are superior compared to either medication alone in improving FEV\textsubscript{1} and symptoms.\textsuperscript{135} Treatment with formoterol and tiotropium in separate inhalers has a bigger impact on FEV\textsubscript{1} than either component alone.\textsuperscript{136} There are numerous combinations of a LABA and LAMA in a single inhaler available. These combinations improve lung function compared to placebo\textsuperscript{133}; this improvement is consistently greater than long acting
bronchodilator monotherapy effects although the magnitude of improvement is less than the fully additive effect predicted by the individual component responses. In studies where patient reported outcomes (PROs) are the primary endpoint or in pooled analyses, combination bronchodilators have a greater impact on PROs compared to monotherapies. In one clinical trial, combination LABA/LAMA treatment had the greatest improvement in quality of life compared to placebo or its individual bronchodilator components in patients with a greater baseline symptom burden. A clinical trial showed that LABA/LAMA improved lung function and symptoms versus long-acting bronchodilator monotherapy in symptomatic patients with low exacerbation risk and not receiving inhaled corticosteroids. These clinical trials deal with group mean data, but symptom responses to LABA/LAMA combinations are best evaluated on an individual patient basis. A lower dose, twice daily regimen for a LABA/LAMA has also been shown to improve symptoms and health status in COPD patients (see Table). These findings have been shown in people across different ethnic groups (Asian as well as European).

Most studies with LABA/LAMA combinations have been performed in patients with a low rate of exacerbations. One study in patients with a history of exacerbations indicated that a combination of long-acting bronchodilators is more effective than long-acting bronchodilator monotherapy for preventing exacerbations. Another large study found that combining a LABA with a LAMA did not reduce exacerbation rate as much as expected compared with a LAMA alone. Another study in patients with a history of exacerbations confirmed that a combination LABA/LAMA decreased exacerbations to a greater extent than an LABA/ICS combination. However, another study in a population with high exacerbation risk (≥ 2 exacerbations and/or 1 hospitalization in the previous year) reported that LABA/ICS decreased exacerbations to a greater extent than an LABA/LAMA combination at higher blood eosinophil concentrations (see Chapter 2). A large observational pharmaco-epidemiological study found similar effectiveness of LABA/LAMA and LABA/ICS but a significantly higher risk of pneumonia in those treated with LABA/ICS.

### BRONCHODILATORS IN STABLE COPD

- Inhaled bronchodilators in COPD are central to symptom management and commonly given on a regular basis to prevent or reduce symptoms (Evidence A).
- Regular and as-needed use of SABA or SAMA improves FEV₁ and symptoms (Evidence A).
- Combinations of SABA and SAMA are superior compared to either medication alone in improving FEV₁ and symptoms (Evidence A).
- LABAs and LAMAs significantly improve lung function, dyspnea, health status, and reduce exacerbation rates (Evidence A).
- LAMAs have a greater effect on exacerbation reduction compared with LABAs (Evidence A) and decrease hospitalizations (Evidence B).
- Combination treatment with a LABA and LAMA increases FEV₁ and reduces symptoms compared to monotherapy (Evidence A).
- Combination treatment with a LABA/LAMA reduces exacerbations compared to monotherapy (Evidence B).
- Tiotropium improves the effectiveness of pulmonary rehabilitation in increasing exercise performance (Evidence B).
- Theophylline exerts a small bronchodilator effect in stable COPD (Evidence A) and that is associated with modest symptomatic benefits (Evidence B).
**Anti-inflammatory agents**

To date, exacerbations (e.g., exacerbation rate, patients with at least one exacerbation, time-to-first exacerbation) represent the main clinically relevant end-point used for efficacy assessment of drugs with anti-inflammatory effects (see Table).

**Inhaled corticosteroids (ICS)**

*Preliminary general considerations.* *In vitro* evidence suggests that COPD-associated inflammation has limited responsiveness to corticosteroids. Moreover, some drugs including beta₂-agonists, theophylline or macrolides may partially facilitate corticosteroid sensitivity in COPD.¹⁵¹,¹⁵² The clinical relevance of this effect has not yet been fully established.

*In vivo* data suggest that the dose-response relationships and long-term (> 3 years) safety of ICS in patients with COPD are unclear and require further investigation.¹⁴⁸ Because the effects of ICS in COPD can be modulated by the concomitant use of long-acting bronchodilators, these two therapeutic options are discussed separately.

Both current and ex-smokers with COPD benefit from ICS use in terms of lung function and exacerbation rates, although the magnitude of the effect is lower in heavy or current smokers compared to light or ex-smokers. ¹⁴⁹,¹⁵³

**Efficacy of ICS (alone).** Most studies have found that regular treatment with ICS alone does not modify the long-term decline of FEV₁ nor mortality in patients with COPD.¹⁵⁴ Studies and meta-analyses assessing the effect of regular treatment with ICS alone on mortality in patients with COPD have not provided conclusive evidence of benefit.¹⁵⁴ In the TORCH trial, a trend toward higher mortality was observed for patients treated with fluticasone propionate alone compared to those receiving salmeterol or fluticasone propionate combination.¹⁵⁵ However, an increase in mortality was not observed in COPD patients treated with fluticasone furoate in the Survival in Chronic Obstructive Pulmonary Disease with Heightened Cardiovascular Risk (SUMMIT) trial.¹⁵⁶ However, in moderate COPD, fluticasone furoate alone or in combination with vilanterol was associated with slower decline in FEV₁ compared with placebo or vilanterol alone by an average 9 ml/year.¹⁵⁷ A number of studies have investigated whether there is a relationship between ICS treatment and risk of lung cancer with conflicting results.¹⁵⁸

**ICS in combination with long-acting bronchodilator therapy.** In patients with moderate to very severe COPD and exacerbations, an ICS combined with a LABA is more effective than either component alone in improving lung function, health status and reducing exacerbations.¹⁵⁹,¹⁶⁰ Clinical trials powered on all-cause mortality as the primary outcome failed to demonstrate a statistically significant effect of combination therapy on survival.¹⁵⁵,¹⁵⁷

Most studies that found a beneficial effect of LABA/ICS fixed dose combination (FDC) over LABA alone on exacerbation rate, recruited patients with a history of at least one exacerbation in the previous year.¹⁵⁹ A pragmatic RCT conducted in a primary healthcare setting in the United Kingdom compared a LABA/ICS combination with usual care. Findings showed an 8.4% reduction in moderate-to-severe exacerbations (primary outcome) and a significant improvement in CAT™ score, with no difference in the rate of healthcare contacts or pneumonias. However, basing recommendations on these results is difficult because of the heterogeneity of treatments reported in the usual care group, the higher rate of treatment changes in the group receiving the LABA/ICS combination of interest, and the medical practice patterns unique to the UK region where the study was conducted.¹⁶¹

**Blood eosinophil count.** A number of studies have shown that blood eosinophil counts predict the magnitude of the effect of ICS (added on top of regular maintenance bronchodilator treatment) in preventing future exacerbations.¹⁴⁹,¹⁶²-¹⁶⁶ There is a continuous relationship between blood eosinophil counts and ICS effects; no and/or small effects are observed at lower eosinophil counts, with incrementally increasing effects observed at higher eosinophil counts. Data modelling indicates that ICS containing regimens have little or no effect at a blood eosinophil
count < 100 cells/µL,

therefore this threshold can be used to identify patients with a low likelihood of treatment benefit with ICS. In addition, lower blood and sputum eosinophils are associated with greater presence of proteobacteria, notably haemophilus, and increased bacterial infections and pneumonia. Lower blood eosinophil counts therefore may identify individuals with microbiome profiles associated with increased risk of clinical worsenings due to pathogenic bacterial species. The threshold of a blood eosinophil count ≥ 300 cells/µL identifies the top of the continuous relationship between eosinophils and ICS, and can be used to identify patients with the greatest likelihood of treatment benefit with ICS.

There is evidence that on average blood eosinophil counts are higher in COPD patients, although there is overlap with controls. Higher blood eosinophil counts in COPD patients are associated with increased lung eosinophil numbers and the presence of higher levels of markers of type-2 inflammation in the airways. These differences in airway inflammation may explain the differential response to ICS treatment according to blood eosinophil counts.

The thresholds of < 100 cells/µL and ≥ 300 cells/µL should be regarded as estimates, rather than precise cut-off values, that can predict different probabilities of treatment benefit.

Sources of evidence include: 1) Post-hoc analyses comparing LABA/ICS versus LABA, 2) Pre-specified analyses comparing triple therapy versus LABA/LAMA or LAMA and, 3) other analyses comparing LABA/ICS versus LABA/LAMA or studying ICS withdrawal.

The treatment effect of ICS containing regimens (LABA/LAMA/ICS and LABA/ICS vs LABA/LAMA) is higher in patients with high exacerbation risk (≥ 2 exacerbations and / or 1 hospitalization in the previous year). Thus, the use of blood eosinophil counts to predict ICS effects should always be combined with clinical assessment of exacerbation risk (as indicated by the previous history of exacerbations). Other factors (smoking status, ethnicity, geographical location) could influence the relationship between ICS effect and blood eosinophil count, but remains to be further explored.

The repeatability of blood eosinophil counts in a large primary care population appear reasonable, although greater variability is observed at higher thresholds. Better reproducibility is observed at the lower thresholds (e.g., 100 cells/µL). All in all, therefore, blood eosinophil counts can help clinicians estimate the likelihood of a beneficial preventive response to the addition of ICS to regular bronchodilator treatment, and thus can be used as a biomarker in conjunction with clinical assessment when making decisions regarding ICS use.

Cohort studies have produced differing results with regard to the ability of blood eosinophils to predict future exacerbation outcomes, with either no relationship or a positive relationship reported. Differences between studies are likely to be related to different previous exacerbation histories and ICS use. There is insufficient evidence to recommend that blood eosinophils should be used to predict future exacerbation risk on an individual basis in COPD patients. Greater FEV₁ decline was observed in mild to moderate COPD patients with higher blood eosinophil counts in a population where ICS use was low, highlighting the possible usefulness of blood eosinophil counts as a prognostic biomarker for lung function decline when not confounded by ICS use. In younger individuals without COPD, higher blood eosinophil counts are associated with increased risk of the subsequent development of COPD.

Factors to consider when initiating ICS treatment in combination with one or two long-acting bronchodilators are shown in the Figure.
Adverse effects. There is high quality evidence from randomized controlled trials (RCTs) that ICS use is associated with higher prevalence of oral candidiasis, hoarse voice, skin bruising and pneumonia.\textsuperscript{154} This excess risk has been confirmed in ICS studies using fluticasone furoate, even at low doses.\textsuperscript{188} Patients at higher risk of pneumonia include those who currently smoke, are aged $\geq 55$ years, have a history of prior exacerbations or pneumonia, a body mass index (BMI) $< 25$ kg/m\textsuperscript{2}, a poor MRC dyspnea grade and/or severe airflow limitation.\textsuperscript{189,190} Independent of ICS use, there is evidence that a blood eosinophil count $< 2\%$ increases the risk of developing pneumonia.\textsuperscript{191} In studies of patients with moderate COPD, ICS by itself or in combination with a LABA did not increase the risk of pneumonia.\textsuperscript{156,190}
Results from RCTs have yielded varied results regarding the risk of decreased bone density and fractures with ICS treatment, which may be due to differences in study designs and/or differences between ICS compounds.\textsuperscript{92,188,192-194} Results of observational studies suggest that ICS treatment could also be associated with increased risk of diabetes/poor control of diabetes,\textsuperscript{195} cataracts,\textsuperscript{196} and mycobacterial infection\textsuperscript{197} including tuberculosis.\textsuperscript{198,199} In the absence of RCT data on these issues, it is not possible to draw firm conclusions.\textsuperscript{200} An increased risk of tuberculosis has been found in both observational studies and a meta-analysis of RCTs.\textsuperscript{198,199}
Withdrawal of ICS. Results from withdrawal studies provide equivocal results regarding consequences of withdrawal on lung function, symptoms and exacerbations.\textsuperscript{201-205} Some studies, but not all, have shown an increase in exacerbations and/or symptoms following ICS withdrawal, while others have not. There has been evidence for a modest decrease in FEV\textsubscript{1} (approximately 40 mL) with ICS withdrawal,\textsuperscript{205} which could be associated with increased baseline circulating eosinophil level.\textsuperscript{176} A study examining ICS withdrawal on a background of dual bronchodilator therapy demonstrated that both FEV\textsubscript{1} loss and an increase in exacerbation frequency associated with ICS withdrawal was greatest among patients with a blood eosinophil count $\geq$ 300 cells/$\mu\text{l}$ at baseline.\textsuperscript{178} Differences between studies may relate to differences in methodology, including the use of background long-acting bronchodilator medication(s) which may minimize any effect of ICS withdrawal.

Triplet therapy (LABA/LAMA/ICS)
The step up in inhaled treatment to LABA plus LAMA plus ICS (triplet therapy) can occur by various approaches\textsuperscript{206} and has been shown to improve lung function, patient reported outcomes and reduce exacerbations when compared to LAMA alone, LABA/LAMA and LABA/ICS.\textsuperscript{149,164,166,207-214}

A post-hoc pooled analysis of three triplet therapy clinical trials in COPD patients with severe airflow limitation and a history of exacerbations showed a non-significant trend for lower mortality (assessed as a safety outcome) with triplet inhaled therapy compared to non-ICS based treatments.\textsuperscript{215} Two large one-year randomized controlled trials reviewed below (named IMPACT and ETHOS) provide new evidence on mortality reduction with fixed-dose inhaled triplet combinations compared to dual bronchodilation.\textsuperscript{216,217} Both trials compared a fixed triplet (LABA/LAMA/ICS) combination (at two ICS dosages in ETHOS) to two dual therapy options (LABA/LAMA and LABA/ICS). They were enriched for symptomatic patients with a history of frequent and/or severe exacerbations. The majority of patients were receiving open triple or LABA/ICS based therapy before study randomization. While mortality was not a primary endpoint for either study, it was a pre-specified outcome; vital status was rigorously collected so that missing data was minimal. Both studies performed intention to treat analyses. In IMPACT (n=10,355), mortality in the triple therapy arm was significantly lower compared to the dual bronchodilation arm but not to LABA/ICS.\textsuperscript{216} In ETHOS (n=8,509) similar findings were observed with the higher dose ICS (but not the lower dose).\textsuperscript{217,218} For both studies, there were no differences versus LABA/ICS.

Together these results suggest a beneficial effect of fixed-dose triplet inhaled therapy versus fixed-dose LABA/LAMA combinations on mortality in symptomatic COPD patients with a history of frequent and/or severe exacerbations who were previously receiving maintenance therapy with triple therapy, LABA/ICS or single or dual long-acting bronchodilators. Further analyses or studies may help determining whether other specific patient subgroups demonstrate a greater survival benefit.

Oral glucocorticoids
Oral glucocorticoids have numerous side effects, including steroid myopathy\textsuperscript{219} which can contribute to muscle weakness, decreased functionality, and respiratory failure in subjects with very severe COPD. Systemic glucocorticoids for treating acute exacerbations in hospitalized patients, or during emergency department visits, have been shown to reduce the rate of treatment failure, the rate of relapse and improve lung function and breathlessness.\textsuperscript{220} Conversely, prospective studies on the long-term effects of oral glucocorticoids in stable COPD are limited.\textsuperscript{221,222} Therefore, while oral glucocorticoids play a role in the acute management of exacerbations, they have no role in the chronic daily treatment in COPD because of a lack of benefit balanced against a high rate of systemic complications.

Phosphodiesterase-4 (PDE4) inhibitors
\textbf{Efficacy.} The principal action of PDE4 inhibitors is to reduce inflammation by inhibiting the breakdown of intracellular cyclic AMP.\textsuperscript{223} Roflumilast is a once daily oral medication with no direct bronchodilator activity. Roflumilast reduces
moderate and severe exacerbations treated with systemic corticosteroids in patients with chronic bronchitis, severe to very severe COPD, and a history of exacerbations. The effects on lung function are also seen when roflumilast is added to long-acting bronchodilators, and in patients who are not controlled on fixed-dose LABA/ICS combinations. The beneficial effects of roflumilast have been reported to be greater in patients with a prior history of hospitalization for an acute exacerbation. There has been no study directly comparing roflumilast with an inhaled corticosteroid.

**Adverse effects.** PDE4 inhibitors have more adverse effects than inhaled medications for COPD. The most frequent are diarrhea, nausea, reduced appetite, weight loss, abdominal pain, sleep disturbance, and headache. Roflumilast should also be used with caution in patients with depression.

**Antibiotics**

- In older studies prophylactic, *continuous* use of antibiotics had no effect on the frequency of exacerbations in COPD and a study that examined the efficacy of chemoprophylaxis undertaken in winter months over a period of 5 years concluded that there was no benefit.
- Later studies have shown that regular use of some antibiotics may reduce exacerbation rate.
- Azithromycin (250 mg/day or 500 mg three times per week) or erythromycin (250 mg two times per day) for one year in patients prone to exacerbations reduced the risk of exacerbations compared to usual care.

**Adverse effects.** Azithromycin use was associated with an increased incidence of bacterial resistance, prolongation of QTc interval, and impaired hearing tests.

**Mucolytic (mucokinetics, mucoregulators) and antioxidant agents (NAC, carbocysteine, erdosteine)**

- In COPD patients not receiving ICS, regular treatment with mucolytics such as carbocysteine and N-acetylcysteine may reduce exacerbations and modestly improve health status.
- In contrast, it has been shown that erdosteine may have a significant effect on (mild) exacerbations irrespective of concurrent treatment with ICS. Due to the heterogeneity of studied populations, treatment dosing and concomitant treatments, currently available data do not allow one to identify precisely the potential target population for antioxidant agents in COPD.

**Other drugs with potential to reduce exacerbations**

Two RCTs in COPD patients performed before 2005 that investigated the use of an immunoregulator reported a decrease in the severity and frequency of exacerbations. Additional studies are needed to examine the long-term effects of this therapy in patients receiving currently recommended COPD maintenance therapy.

Four large phase 3 studies have investigated the efficacy of the anti-IL-5 monoclonal antibody mepolizumab and the anti-IL-5 receptor-α antibody benralizumab in patients with severe COPD, recurrent exacerbations and peripheral blood evidence of eosinophilic inflammation despite high intensity inhaled therapy. The studies showed a 15-20% reduction in the rate of severe exacerbations but the effect was not always statistically significant and it was variable between studies and doses. There was no effect on FEV1 or quality of life scores and no consistent relationship between the response to treatment and the peripheral blood eosinophil count. A post-hoc analysis of the mepolizumab trial showed greater benefit and more clear evidence of a blood eosinophil related treatment effect against oral corticosteroid treated exacerbations raising the possibility that this treatment might find a role in a highly selected subgroup of patients with eosinophilic COPD and frequent requirement for oral corticosteroids. Further studies are required to investigate this possibility.

Nedocromil and leukotriene modifiers have not been tested adequately in COPD patients and the available evidence
does not support their use.\textsuperscript{246,247}

There was no evidence of benefit, and some evidence of harm, including malignancy and pneumonia, following treatment with an anti-TNF-alpha antibody (infliximab) in moderate to severe COPD.\textsuperscript{248}

An RCT of the selective β1 receptor blocker metoprolol in patients with moderate or severe COPD, who did not have an established indication for beta-blocker use, showed it did not delay the time until the first COPD exacerbation compared placebo group and hospitalization for exacerbation was more common among the patients treated with metoprolol.\textsuperscript{249} There is no evidence that beta-blockers should be used in patients with COPD who do not have a cardiovascular indication for their use.

Simvastatin did not prevent exacerbations in patients with COPD who had no metabolic or cardiovascular indication for statin treatment.\textsuperscript{250} An association between statin use and improved outcomes (including decreased exacerbations and mortality) has been reported in observational studies of patients with COPD who received them for cardiovascular and metabolic indications.\textsuperscript{251}

There is no evidence that supplementation with vitamin D has a positive impact on exacerbations in unselected patients.\textsuperscript{252} In a meta-analysis vitamin D supplementation reduced exacerbation rates in patients with low baseline vitamin D levels.\textsuperscript{253}

Other pharmacological treatments

<table>
<thead>
<tr>
<th>OTHER PHARMACOLOGICAL TREATMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALPHA-1 ANTITRYPSIN AUGMENTATION THERAPY</td>
</tr>
<tr>
<td>• Intravenous augmentation therapy may slow down the progression of emphysema (Evidence B).</td>
</tr>
<tr>
<td>ANTITUSSIVES</td>
</tr>
<tr>
<td>• There is no conclusive evidence of a benefical role of antitussives in patients with COPD (Evidence C).</td>
</tr>
<tr>
<td>VASODILATORS</td>
</tr>
<tr>
<td>• Vasodilators do not improve outcomes and may worsen oxygenation (Evidence B).</td>
</tr>
</tbody>
</table>

REHABILITATION, EDUCATION & SELF-MANAGEMENT

Pulmonary rehabilitation

Pulmonary rehabilitation is defined as “a comprehensive intervention based on thorough patient assessment followed by patient-tailored therapies that include, but are not limited to, exercise training, education, self-management intervention aiming at behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.”\textsuperscript{254} The benefits to COPD patients from pulmonary rehabilitation are considerable (see Table), and rehabilitation has been shown to be the most effective therapeutic strategy to improve shortness of breath, health status and exercise tolerance.\textsuperscript{255}
Symptom control and palliative care

Palliative care is a broad term that encompasses approaches to symptom control as well as management of terminal patients close to death. The goal of palliative care is to prevent and relieve suffering, and to support the best possible quality of life for patients and their families, regardless of the stage of disease or the need for other therapies. COPD is a highly symptomatic disease and has many elements such as fatigue, dyspnea, depression, anxiety, insomnia that require symptom-based palliative treatments. There is evidence that patients with COPD are less likely to receive such services compared to patients with lung cancer. Palliative care expands traditional disease-model medical treatment to increase the focus on the goals of enhancing quality of life, optimizing function, helping with decision-making about end-of-life care, and providing emotional and spiritual support to patients and their families. Palliative approaches are essential in the context of end-of-life care as well as hospice care (a model for delivery of end-of-life care for patients who are terminally ill and predicted to have less than 6 months to live). Increasingly, palliative care teams are available for consultation for hospitalized patients. Availability for outpatient palliative care consultation is less common, and has been shown to improve quality of life, reduce symptoms and even prolong survival for patients with advanced lung cancer.

Even when receiving optimal medical therapy many patients with COPD continue to experience distressing breathlessness, impaired exercise capacity, fatigue, and suffer panic, anxiety and depression. Some of these symptoms can be improved by wider use of palliative therapies that in the past have often been restricted to end-of-life situations.
OTHER TREATMENTS

OXYGEN THERAPY AND VENTILATORY SUPPORT IN STABLE COPD

OXYGEN THERAPY

• The long-term administration of oxygen increases survival in patients with severe chronic resting arterial hypoxemia (Evidence A).

• In patients with stable COPD and moderate resting or exercise-induced arterial desaturation, prescription of long-term oxygen does not lengthen time to death or first hospitalization or provide sustained benefit in health status, lung function and 6-minute walk distance (Evidence A).

• Resting oxygenation at sea level does not exclude the development of severe hypoxemia when traveling by air (Evidence C).

VENTILATORY SUPPORT

• NPPV may improve hospitalization-free survival in selected patients after recent hospitalization, particularly in those with pronounced daytime persistent hypercapnia (PaCO₂ ≥ 52 mmHg) (Evidence B).

INTERVENTIONAL THERAPY

Surgical Interventions

Surgical interventions include lung volume reduction surgery (LVRS), bullectomy and lung transplantation (see Table).

INTERVENTIONAL THERAPY IN STABLE COPD

LUNG VOLUME REDUCTION SURGERY

• Lung volume reduction surgery improves survival in severe emphysema patients with an upper-lobe emphysema and low post-rehabilitation exercise capacity (Evidence A).

BULLECTOMY

• In selected patients, bullectomy is associated with decreased dyspnea, improved lung function and exercise tolerance (Evidence C).

TRANSPLANTATION

• In appropriately selected patients with very severe COPD, lung transplantation has been shown to improve quality of life and functional capacity (Evidence C).

BRONCHOSCOPIC INTERVENTIONS

• In select patients with advanced emphysema, bronchoscopic interventions reduce end-expiratory lung volume and improve exercise tolerance, health status and lung function at 6-12 months following treatment. Endobronchial valves (Evidence A); Lung coils (Evidence B); Vapor ablation (Evidence B).
Bronchoscopic interventions to reduce hyperinflation in severe emphysema

Due to the morbidity and mortality associated with LVRS, less invasive bronchoscopic approaches to lung reduction have been examined. These include a variety of different bronchoscopic procedures (see Table).

MANAGEMENT OF STABLE COPD

OVERALL KEY POINTS:

- The management strategy for stable COPD should be predominantly based on the individualized assessment of symptoms and future risk of exacerbations.
- All individuals who smoke should be strongly encouraged and supported to quit.
- The main treatment goals are reduction of symptoms and future risk of exacerbations.
- Management strategies include pharmacologic and non-pharmacologic interventions.

COPD patients should have an assessment of the severity of their airflow obstruction, symptoms, history of exacerbations, exposure to risk factors and comorbidities (see Figure) to guide management. The assessment is summarized in Chapter 2.

We propose a tailored approach to initiate treatment based on the level of symptoms and risk for exacerbations. Treatment can be escalated/de-escalated based on the presence of the predominant symptoms of breathlessness and exercise limitation, and the continued occurrence of exacerbations whilst on maintenance therapy. The basis for these recommendations, which propose an organized approach to treatment, was partly derived from evidence generated from randomized controlled trials. However, as these recommendations are intended to support clinician decision-making, they also incorporate expert advice based on clinical experience.

It is crucial for people with COPD to understand the nature of the disease, risk factors for its progression, and the role that they and their healthcare workers must play in order to achieve optimal management and health outcomes.

Following the assessment, initial management should address reducing exposure to risk factors including smoking cessation. Vaccination should be offered, and patients should receive general advice on healthy living, including diet, and that physical exercise is safe and encouraged for people with COPD. Initial pharmacotherapy should be based on the patient’s GOLD group (Figure). Patients should be offered guidance on self-management of breathlessness, energy conservation and stress management, and they should be given a written action plan. Comorbidities should also be managed (Figure).

Patients should be reviewed after a suitable interval and their current level of symptoms (using either the CAT or mMRC scores) and exacerbation frequency assessed. The effect of treatment and possible adverse effects should be evaluated, and comorbidities reassessed.

Inhaler technique, adherence to prescribed therapy (both pharmacological and non-pharmacological), smoking status and continued exposure to risk factors should be checked. Physical activity should be encouraged and referral for pulmonary rehabilitation considered. The need for oxygen therapy, ventilatory support, lung volume reduction and palliative approaches should be reviewed. The action plan should be updated. Spirometry should be repeated at least annually.
Pharmacological and non-pharmacological therapy should be adjusted as necessary (see below) and further reviews undertaken (Figure).

The goals for treatment of stable COPD are to improve symptoms, exercise tolerance and health status in addition to reducing risk by preventing disease progression, exacerbations and mortality.

IDENTIFY AND REDUCE EXPOSURE TO RISK FACTORS

Identification and reduction of exposure to risk factors is important in the treatment and prevention of COPD. Cigarette smoking is the most commonly encountered and easily identifiable risk factor for COPD, and smoking cessation should be continually encouraged for all individuals who smoke. Reduction of total personal exposure to occupational dusts, fumes, and gases, and to indoor and outdoor air pollutants, should also be addressed.
Pharmacological therapies can reduce symptoms, and the risk and severity of exacerbations, as well as improve the health status and exercise tolerance of patients with COPD. Most of the drugs are inhaled so proper inhaler technique is highly relevant. Key points for the inhalation of drugs, bronchodilator use, the use of anti-inflammatory agents and the use of pharmacological treatments are summarized in the Tables.

**KEY POINTS FOR INHALATION OF DRUGS**

- The choice of inhaler device has to be individually tailored and will depend on access, cost, prescriber, and most importantly, patient’s ability and preference.

- It is essential to provide instructions and to demonstrate the proper inhalation technique when prescribing a device, to ensure that inhaler technique is adequate and re-check at each visit that patients continue to use their inhaler correctly.

- Inhaler technique (and adherence to therapy) should be assessed before concluding that the current therapy requires modification.

**KEY POINTS FOR THE USE OF BRONCHODILATORS**

- LABAs and LAMAs are preferred over short-acting agents except for patients with only occasional dyspnea (Evidence A), and for immediate relief of symptoms in patients already on long-acting bronchodilators for maintenance therapy.

- Patients may be started on single long-acting bronchodilator therapy or dual long-acting bronchodilator therapy. In patients with persistent dyspnea or one bronchodilator treatment should be escalated to two (Evidence A).

- Inhaled bronchodilators are recommended over oral bronchodilators (Evidence A).

- Theophylline is not recommended unless other long-term treatment bronchodilators are unavailable or unaffordable (Evidence B).
Algorithms for the assessment, initiation and follow-up management of pharmacological treatment

A model for the INITIATION of pharmacological management of COPD according to the individualized assessment of symptoms and exacerbation risk following the ABCD assessment scheme is shown. There is a lack of high-quality evidence supporting initial pharmacological treatment strategies in newly diagnosed COPD patients. However, a real-world observational study has demonstrated that initial COPD treatment with an LABA/ICS is more effective than treatment with a LAMA in patients with previous exacerbations and high blood eosinophils ≥ 300 cells/µL. The Figure below is an attempt to provide clinical guidance using the best available evidence.
**Definition of abbreviations:** eos: blood eosinophil count in cells per microliter; mMRC: modified Medical Research Council dyspnea questionnaire; CAT™: COPD Assessment Test™.

Following implementation of therapy, patients should be reassessed for attainment of treatment goals and identification of any barriers for successful treatment. Following review of the patient response to treatment initiation, adjustments in pharmacological treatment may be needed.

A separate algorithm is provided for **FOLLOW-UP** treatment, where the management is still based on symptoms and exacerbations, but the recommendations do not depend on the patient’s GOLD group at diagnosis (see next Figure). These follow-up recommendations are designed to facilitate management of patients taking maintenance treatment(s), whether early after initial treatment or after years of follow-up. These recommendations incorporate recent evidence from clinical trials and the use of peripheral blood eosinophil counts as a biomarker to guide the use of ICS therapy for exacerbation prevention.

The Figure suggests escalation and de-escalation strategies based on available efficacy as well as safety data. The response to treatment escalation should always be reviewed, and de-escalation should be considered if there is a lack of clinical benefit and/or side effects occur. De-escalation may also be considered in COPD patients receiving treatment who return with resolution of some symptoms that subsequently may require less therapy. Patients, in whom treatment modification is considered, in particular de-escalation, should be undertaken under close medical supervision. We are fully aware that treatment escalation has not been systematically tested; trials of de-escalation are also limited and only include ICS.

**Initial pharmacological management**
Rescue short-acting bronchodilators should be prescribed to all patients for immediate symptom relief.

**Group A**
- All Group A patients should be offered bronchodilator treatment based on its effect on breathlessness. This can be either a short- or a long-acting bronchodilator.

- This should be continued if benefit is documented.
**Group B**

- Initial therapy should consist of a long acting bronchodilator. Long-acting inhaled bronchodilators are superior to short-acting bronchodilators taken as needed i.e., *pro re nata* (prn) and are therefore recommended.\(^{265,266}\)

- There is no evidence to recommend one class of long-acting bronchodilators over another for initial relief of symptoms in this group of patients. In the individual patient, the choice should depend on the patient’s perception of symptom relief.

- For patients with severe breathlessness initial therapy with two bronchodilators may be considered.\(^{142}\)

- Group B patients are likely to have comorbidities that may add to their symptomatology and impact their prognosis, and these possibilities should be investigated.\(^{267,268}\)

**Group C**

- Initial therapy should consist of a single long acting bronchodilator. In two head-to-head comparisons\(^{118,269}\) the tested LAMA was superior to the LABA regarding exacerbation prevention (for details see Chapter 3) therefore we recommend starting therapy with a LAMA in this group.
Group D

► In general, therapy can be started with a LAMA as it has effects on both breathlessness and exacerbations (see Chapter 3).

► For patients with more severe symptoms (order of magnitude of CAT™ ≥ 20), especially driven by greater dyspnea and / or exercise limitation, LAMA/LABA may be chosen as initial treatment based on studies with patient reported outcomes as the primary endpoint where LABA/LAMA combinations showed superior results compared to the single substances (see Chapter 3). An advantage of LABA/LAMA over LAMA for exacerbation prevention has not been consistently demonstrated, so the decision to use LABA/LAMA as initial treatment should be guided by the level of symptoms.

► In some patients, initial therapy with LABA/ICS may be the first choice; this treatment has the greatest likelihood of reducing exacerbations in patients with blood eosinophil counts ≥ 300 cells/µL. LABA/ICS may also be first choice in COPD patients with a history of asthma.

► ICS may cause side effects such as pneumonia, so should be used as initial therapy only after the possible clinical benefits versus risks have been considered.

Follow-up pharmacological management

The follow-up pharmacological treatment algorithm can be applied to any patient who is already taking maintenance treatment(s) irrespective of the GOLD group allocated at treatment initiation. The need to treat primarily dyspnea/exercise limitation or prevent exacerbations further should be evaluated. If a change in treatment is considered necessary then select the corresponding algorithm for dyspnea or exacerbations; the exacerbation algorithm should also be used for patients who require a change in treatment for both dyspnea and exacerbations. Identify which box corresponds to the patient’s the current treatment.

Follow up pharmacological management should be guided by the principles of first review and assess, then adjust if needed:

► Review
  ▪ Review symptoms (dyspnea) and exacerbation risk.

► Assess
  ▪ Assess inhaler technique and adherence, and the role of non-pharmacological approaches (covered later in this chapter).

► Adjust
  ▪ Adjust pharmacological treatment, including escalation or de-escalation. Switching inhaler device or molecules within the same class (e.g. using a different long acting bronchodilator) may be considered as appropriate. Any change in treatment requires a subsequent review of the clinical response, including side effects.

Dyspnea

► For patients with persistent breathlessness or exercise limitation on long acting bronchodilator monotherapy, the use of two bronchodilators is recommended.
  ▪ If the addition of a second long acting bronchodilator does not improve symptoms, we suggest the treatment could be stepped down again to monotherapy. Switching inhaler device or molecules can also be considered.
For patients with persistent breathlessness or exercise limitation on LABA/ICS treatment, LAMA can be added to escalate to triple therapy.

- Alternatively, switching from LABA/ICS to LABA/LAMA should be considered if the original indication for ICS was inappropriate (e.g., an ICS was used to treat symptoms in the absence of a history of exacerbations), or there has been a lack of response to ICS treatment, or if ICS side effects warrant discontinuation.

At all stages, dyspnea due to other causes (not COPD) should be investigated and treated appropriately. Inhaler technique and adherence should be considered as causes of inadequate treatment response.

**Exacerbations**

- For patients with persistent exacerbations on long acting bronchodilator monotherapy, escalation to either LABA/LAMA or LABA/ICS is recommended. LABA/ICS may be preferred for patients with a history or findings suggestive of asthma. Blood eosinophil counts may identify patients with a greater likelihood of a beneficial response to ICS. For patients with one exacerbation per year, a peripheral blood level ≥ 300 eosinophils/µL identifies patients more likely to respond to LABA/ICS treatment.\(^{162,163}\) For patients with ≥ 2 moderate exacerbations per year or at least one severe exacerbation requiring hospitalization in the prior year, LABA/ICS treatment can be considered at blood eosinophil counts ≥ 100 cells/µL, as ICS effects are more pronounced in patients with greater exacerbation frequency and/or severity.\(^{149}\)

In patients who develop further exacerbations on LABA/LAMA therapy we suggest two alternative pathways. Blood eosinophil counts < 100 cells/µL can be used to predict a low likelihood of a beneficial ICS response:

- Escalation to LABA/LAMA/ICS. A beneficial response after the addition of ICS may be observed at blood eosinophil counts ≥ 100 cells /µL, with a greater magnitude of response more likely with higher eosinophil counts.
- Add roflumilast or azithromycin (see below) if blood eosinophils < 100 cells/µL.

In patients who develop further exacerbations on LABA/ICS therapy, we recommend escalation to triple therapy by adding a LAMA.\(^{149,214}\) Alternatively, treatment can be switched to LABA/LAMA if there has been a lack of response to ICS treatment, or if ICS side effects warrant discontinuation.

If patients treated with LABA/LAMA/ICS who still have exacerbations the following options may be considered:

- **Add roflumilast.** This may be considered in patients with an FEV\(_1\) < 50% predicted and chronic bronchitis,\(^{226}\) particularly if they have experienced at least one hospitalization for an exacerbation in the previous year.\(^{227,271}\)
- **Add a macrolide.** The best available evidence exists for the use of azithromycin, especially in those who are not current smokers.\(^{228,237}\) Consideration to the development of resistant organisms should be factored into decision-making.
- **Stopping ICS.** This can be considered if there are adverse effects (such as pneumonia) or a reported lack of efficacy. However, a blood eosinophil count ≥ 300 cells /µL identifies patients with the greatest likelihood of experiencing more exacerbations after ICS withdrawal and who subsequently should be followed closely for relapse of exacerbations.\(^{177,178}\)
TREATMENT OF STABLE COPD: NON-PHARMACOLOGICAL TREATMENT

Non-pharmacological treatment is complementary to pharmacological treatment and should form part of the comprehensive management of COPD.

After receiving a diagnosis of COPD a patient should be given further information about the condition. Physicians should emphasize the importance of a smoke free environment, prescribe vaccinations, empower adherence to prescribed medication, ensure proper inhaler technique, promote physical activity and refer patients (GOLD B - GOLD D) to pulmonary rehabilitation.

Some relevant non-pharmacological measures based on the GOLD group AT DIAGNOSIS are summarized in the Table.

<table>
<thead>
<tr>
<th>PATIENT GROUP</th>
<th>ESSENTIAL</th>
<th>RECOMMENDED</th>
<th>DEPENDING ON LOCAL GUIDELINES</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Smoking Cessation (can include pharmacologic treatment)</td>
<td>Physical Activity</td>
<td>Flu Vaccination</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pneumococcal Vaccination</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pertussis Vaccination</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Covid-19 Vaccination</td>
</tr>
<tr>
<td>B, C and D</td>
<td>Smoking Cessation (can include pharmacologic treatment)</td>
<td>Physical Activity</td>
<td>Flu Vaccination</td>
</tr>
<tr>
<td></td>
<td>Pulmonary Rehabilitation</td>
<td></td>
<td>Pneumococcal Vaccination</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pertussis Vaccination</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Covid-19 Vaccination</td>
</tr>
</tbody>
</table>

*Can include pharmacologic treatment.
Recommendations for **FOLLOW UP** non-pharmacological treatments are based on patient’s treatable traits e.g., symptoms and exacerbations (Table).

### FOLLOW-UP OF NON-PHARMACOLOGICAL TREATMENT

1. **IF RESPONSE TO INITIAL TREATMENT IS APPROPRIATE, MAINTAIN IT AND OFFER:**
   - Flu vaccination every year and other recommended vaccinations according to guidelines
   - Self-management education
   - Assessment of behavioral risk factors such as smoking cessation (if applicable) and environmental exposures

   Ensure
   - Maintenance of exercise program and physical activity
   - Adequate sleep and a healthy diet

2. **IF NOT, CONSIDER THE PREDOMINANT TREATABLE TRAIT TO TARGET**

   - **DYSPNEA**
     - Self-management education (written action plan) with integrated self-management regarding:
     - Breathlessness and energy conservation techniques, and stress management strategies
     - Pulmonary rehabilitation (PR) program and/or maintenance exercise program post PR

   - **EXACERBATIONS**
     - Self-management education (written action plan) that is personalized with respect to:
     - Avoidance of aggravating factors
     - How to monitor/manage worsening of symptoms
     - Contact information in the event of an exacerbation

---

**Education and self-management**

Self-management education and coaching by healthcare professionals should be a major component of the “Chronic Care Model” within the context of the healthcare delivery system.

The aim of self-management interventions is to motivate, engage and coach patients to positively adapt their health behavior(s) and develop skills to better manage their COPD on a day-to-day basis. Physicians and healthcare providers need to go beyond pure education/advice-giving (didactic) approaches to help patients learn and adopt sustainable self-management skills. The basis of enabling patients to become active partners in their ongoing care is to build knowledge and skills. It is important to recognize that patient education alone does not itself change behavior or even motivate patients, and it has had no impact on improving exercise performance or lung function, but it can play a role in improving skills, ability to cope with illness, and health status.
Oxygen therapy
An appropriate algorithm for the prescription of oxygen to COPD patients is shown below.

**PRESRIPTION OF SUPPLEMENTAL OXYGEN TO COPD PATIENTS**

Arterial hypoxemia defined as:
- $\text{PaO}_2 < 55 \text{ mmHg (7.3 kPa)}$ or $\text{SaO}_2 < 88$
- or
- $\text{PaO}_2 > 55 \text{ but < 60 mmHg (> 7.3 kPa but < 8 kPa)}$
  with right heart failure or erythrocytosis

Prescribe supplemental oxygen and titrate to keep $\text{SaO}_2 \geq 90$

Recheck in 60 to 90 days to assess:
- If supplemental oxygen is still indicated
- If prescribed supplemental oxygen is effective
Key points for the use of non-pharmacological treatments are given in the following Table.

**KEY POINTS FOR THE USE OF NON-PHARMACOLOGICAL TREATMENTS**

### EDUCATION, SELF-MANAGEMENT AND PULMONARY REHABILITATION

- Education is needed to change patient’s knowledge but there is no evidence that used alone it will change patient behavior.
- Education self-management with the support of a case manager with or without the use of a written action plan is recommended for the prevention of exacerbation complications such as hospital admissions (Evidence B).
- Rehabilitation is indicated in all patients with relevant symptoms and/or a high risk for exacerbation (Evidence A).
- Physical activity is a strong predictor of mortality (Evidence A). Patients should be encouraged to increase the level of physical activity although we still don’t know how to best insure the likelihood of success.

### VACCINATION

- Influenza vaccination is recommended for all patients with COPD (Evidence A).
- Pneumococcal vaccination: the PCV13 and PPVS23 are recommended for all patients >65 years of age, and in younger patients with significant comorbid conditions including chronic heart or lung disease (Evidence B).
- Covid-19 vaccination in line with national recommendations (Evidence B).
- Tdap (dTAP/dTPa) vaccination for adults with COPD who were not vaccinated in adolescence to protect against pertussis (whooping cough) (Evidence B).

### NUTRITION

- Nutritional supplementation should be considered in malnourished patients with COPD (Evidence B).

### END OF LIFE AND PALLIATIVE CARE

- All clinicians managing patients with COPD should be aware of the effectiveness of palliative approaches to symptom control and use these in their practice (Evidence D).
- End of life care should include discussions with patients and their families about their views on resuscitation, advance directives and place of death preferences (Evidence D).

### TREATMENT OF HYPOXEMIA

- In patients with severe resting hypoxemia long-term oxygen therapy is indicated (Evidence A).
- In patients with stable COPD and resting or exercise-induced moderate desaturation, long term oxygen treatment should not be routinely prescribed. However, individual patient factors may be considered when evaluating the patient's needs for supplemental oxygen (Evidence A).
- Resting oxygenation at sea level does not exclude the development of severe hypoxemia when travelling by air (Evidence C).

### TREATMENT OF HYPERCAPNIA

- In patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory failure, long term noninvasive ventilation may be considered (Evidence B).

### INTERVENTION BRONCHOSCOPY AND SURGERY

- Lung volume reduction surgery should be considered in selected patients with upper-lobe emphysema (Evidence A).
- In selected patients with a large bulla surgical bullctomy may be considered (Evidence C).
- In select patients with advanced emphysema, bronchoscopic interventions reduce end-expiratory lung volume and improve exercise tolerance, quality of life and lung function at 6-12 months following treatment. Endobronchial valves (Evidence A); Lung coils (Evidence B); Vapor ablation (Evidence B).
- In patients with very severe COPD (progressive disease, BODE score of 7 to 10, and not candidate for lung volume reduction) lung transplantation may be considered for referral with at least one of the following: (1) history of hospitalization for exacerbation associated with acute hypercapnia (Pco2 >50 mm Hg); (2) pulmonary hypertension and/or cor pulmonale, despite oxygen therapy; or (3) FEV1 < 20% and either DLCO < 20% or homogenous distribution of emphysema (Evidence C).
MONITORING AND FOLLOW-UP

Routine follow-up of COPD patients is essential. Lung function may worsen over time, even with the best available care. Symptoms, exacerbations and objective measures of airflow limitation should be monitored to determine when to modify management and to identify any complications and/or comorbidities that may develop. Based on current literature, comprehensive self-management or routine monitoring has not shown long-term benefits in terms of health status over usual care alone for COPD patients in general practice.²⁷⁵

MANAGEMENT OF EXACERBATIONS

OVERALL KEY POINTS:

- An exacerbation of COPD is defined as an acute worsening of respiratory symptoms that results in additional therapy.

- As the symptoms are not specific to COPD relevant differential diagnoses should be considered.

- Exacerbations of COPD can be precipitated by several factors. The most common causes are respiratory tract infections.

- The goal for treatment of COPD exacerbations is to minimize the negative impact of the current exacerbation and to prevent subsequent events.

- Short-acting inhaled beta₂-agonists, with or without short-acting anticholinergics, are recommended as the initial bronchodilators to treat an acute exacerbation.

- Maintenance therapy with long-acting bronchodilators should be initiated as soon as possible before hospital discharge.

- Systemic corticosteroids can improve lung function (FEV₁), oxygenation and shorten recovery time and hospitalization duration. Duration of therapy should not be more than 5-7 days.

- Antibiotics, when indicated, can shorten recovery time, reduce the risk of early relapse, treatment failure, and hospitalization duration. Duration of therapy should be 5-7 days.

- Methylxanthines are not recommended due to increased side effect profiles.

- Non-invasive mechanical ventilation should be the first mode of ventilation used in COPD patients with acute respiratory failure who have no absolute contraindication because it improves gas exchange, reduces work of breathing and the need for intubation, decreases hospitalization duration and improves survival.

- Following an exacerbation, appropriate measures for exacerbation prevention should be initiated.

An exacerbation of chronic obstructive pulmonary disease (COPD) is defined as an acute worsening of respiratory symptoms that results in additional therapy.²⁷⁶,²⁷⁷ Exacerbations of COPD are important events in the management of COPD because they negatively impact health status, rates of hospitalization and readmission, and disease progression. COPD exacerbations are complex events usually associated with increased airway inflammation, increased mucus production and marked gas trapping. These changes contribute to increased dyspnea that is the key symptom of an exacerbation. Other symptoms include increased sputum purulence and volume, together with increased cough and wheeze.²⁷⁸ As other comorbidities that may worsen respiratory symptoms are common in COPD
patients, clinical assessment to rule out differential diagnoses should be considered before diagnosis of a COPD exacerbation (Table).

### DIFFERENTIAL DIAGNOSIS OF COPD EXACERBATION

**WHEN THERE IS CLINICAL SUSPICION OF THE FOLLOWING ACUTE CONDITIONS, CONSIDER THE FOLLOWING INVESTIGATIONS:**

- **PNEUMONIA**
  - Chest radiograph
  - Assessment of C-reactive protein (CRP) and/or procalcitonin
- **PNEUMOTHORAX**
  - Chest radiograph or ultrasound
- **PLEURAL EFFUSION**
  - Chest radiograph or ultrasound
- **PULMONARY EMBOLISM**
  - D-dimer and/or Doppler sonogram of lower extremities
  - Chest tomography – pulmonary embolism protocol
- **PULMONARY EDEMA DUE TO CARDIAC RELATED CONDITIONS**
  - Electrocardiogram and cardiac ultrasound
  - Cardiac enzymes
- **CARDIAC ARRHYTHMIAS – ATRIAL FIBRILLATION/FLUTTER**
  - Electrocardiogram

Exacerbations are classified as:

- **Mild** (treated with short acting bronchodilators only, SABDs)
- **Moderate** (treated with SABDs plus antibiotics and/or oral corticosteroids) or
- **Severe** (patient requires hospitalization or visits the emergency room). Severe exacerbations may also be associated with acute respiratory failure.

### TREATMENT OPTIONS

#### Treatment setting

The goals of treatment for COPD exacerbations are to minimize the negative impact of the current exacerbation and prevent the development of subsequent events. Depending on the severity of an exacerbation and/or the severity of the underlying disease, an exacerbation can be managed in either the outpatient or inpatient setting. More than 80% of exacerbations are managed on an outpatient basis with pharmacological therapies including bronchodilators, corticosteroids, and antibiotics. When patients with a COPD exacerbation come to the emergency department, they should be provided with supplemental oxygen and undergo assessment to determine whether the exacerbation is life-threatening and if
increased work of breathing or impaired gas exchange requires consideration for non-invasive ventilation (see Table). If so, healthcare providers should consider admission to the respiratory or intensive care unit of the hospital. Otherwise, the patient may be managed in the emergency department or hospital ward unit. In addition to pharmacological therapy, hospital management of exacerbations includes respiratory support (oxygen therapy, ventilation). The management of severe, but not life-threatening, exacerbations is also outlined (see Table).

### POTENTIAL INDICATIONS FOR HOSPITALIZATION ASSESSMENT*

- Severe symptoms such as sudden worsening of resting dyspnea, high respiratory rate, decreased oxygen saturation, confusion, drowsiness.
- Acute respiratory failure.
- Onset of new physical signs (e.g., cyanosis, peripheral edema).
- Failure of an exacerbation to respond to initial medical management.
- Presence of serious comorbidities (e.g., heart failure, newly occurring arrhythmias, etc.).
- Insufficient home support.

*Local resources need to be considered.

### MANAGEMENT OF SEVERE BUT NOT LIFE-THREATENING EXACERBATIONS*

- Assess severity of symptoms, blood gases, chest radiograph.
- Administer supplemental oxygen therapy, obtain serial arterial blood gas, venous blood gas and pulse oximetry measurements.
- Bronchodilators:
  » Increase doses and/or frequency of short-acting bronchodilators.
  » Combine short-acting beta 2-agonists and anticholinergics.
  » Consider use of long-active bronchodilators when patient becomes stable.
  » Use spacers or air-driven nebulizers when appropriate.
- Consider oral corticosteroids.
- Consider antibiotics (oral) when signs of bacterial infection are present.
- Consider noninvasive mechanical ventilation (NIV).
- At all times:
  » Monitor fluid balance.
  » Consider subcutaneous heparin or low molecular weight heparin for thromboembolism prophylaxis.
  » Identify and treat associated conditions (e.g., heart failure, arrhythmias, pulmonary embolism etc.).

*Local resources need to be considered.

The clinical presentation of COPD exacerbation is heterogeneous, thus we recommend that in hospitalized patients the severity of the exacerbation should be based on the patient’s clinical signs and recommend the following classification.²⁸²

**No respiratory failure:** Respiratory rate: 20-30 breaths per minute; no use of accessory respiratory muscles; no changes in mental status; hypoxemia improved with supplemental oxygen given via Venturi mask 24-35% inspired oxygen (FiO₂); no increase in PaCO₂.

**Acute respiratory failure – non-life-threatening:** Respiratory rate: > 30 breaths per minute; using accessory respiratory
muscles; no change in mental status; hypoxemia improved with supplemental oxygen via Venturi mask ≥ 35% FiO₂; hypercarbia i.e., PaCO₂ increased compared with baseline or elevated 50-60 mmHg.

**Acute respiratory failure – life-threatening:** Respiratory rate: > 30 breaths per minute; using accessory respiratory muscles; acute changes in mental status; hypoxemia not improved with supplemental oxygen via Venturi mask or requiring FiO₂ > 40%; hypercarbia i.e., PaCO₂ increased compared with baseline or elevated > 60 mmHg or the presence of acidosis (pH ≤ 7.25).

The three classes of medications most commonly used for COPD exacerbations are bronchodilators, corticosteroids, and antibiotics (see Table).

### KEY POINTS FOR THE MANAGEMENT OF EXACERBATIONS

- Short-acting inhaled beta₂-agonists, with or without short-acting anticholinergics, are recommended as the initial bronchodilators to treat an acute exacerbation (Evidence C).
- Systemic corticosteroids can improve lung function (FEV₁), oxygenation and shorten recovery time and hospitalization duration. Duration of therapy should not be more than 5-7 days (Evidence A).
- Antibiotics, when indicated, can shorten recovery time, reduce the risk of early relapse, treatment failure, and hospitalization duration. Duration of therapy should be 5-7 days (Evidence B).
- Methylxanthines are not recommended due to increased side effect profiles (Evidence B).
- Non-invasive mechanical ventilation should be the first mode of ventilation used in COPD patients with acute respiratory failure who have no absolute contraindication because it improves gas exchange, reduces work of breathing and the need for intubation, decreases hospitalization duration and improves survival (Evidence A).

### Respiratory support

#### INDICATIONS FOR RESPIRATORY OR MEDICAL INTENSIVE CARE UNIT ADMISSION*

- Severe dyspnea that responds inadequately to initial emergency therapy.
- Changes in mental status (confusion, lethargy, coma).
- Persistent or worsening hypoxemia (PaO₂ < 5.3 kPa or 40mmHg) and/or severe/worsening respiratory acidosis (pH < 7.25) despite supplemental oxygen and noninvasive ventilation.
- Need for invasive mechanical ventilation.
- Hemodynamic instability - need for vasopressors.

*Local resources need to be considered.

#### INDICATIONS FOR NONINVASIVE MECHANICAL VENTILATION (NIV)

At least one of the following:

- Respiratory acidosis (PaCO₂ ≥ 6.0 kPa or 45 mmHg and arterial pH ≤ 7.35).
- Severe dyspnea with clinical signs suggestive of respiratory muscle fatigue, increased work of breathing, or both, such as use of respiratory accessory muscles, paradoxical motion of the abdomen, or retraction of the intercostal spaces.
- Persistent hypoxemia despite supplemental oxygen therapy.
Invasive mechanical ventilation. The indications for initiating invasive mechanical ventilation during an exacerbation are shown in the Table and include failure of an initial trial of NIV.283

**INDICATIONS FOR INVASIVE MECHANICAL VENTILATION**

- Unable to tolerate NIV or NIV failure.
- Status post - respiratory or cardiac arrest.
- Diminished consciousness, psychomotor agitation inadequately controlled by sedation.
- Massive aspiration or persistent vomiting.
- Persistent inability to remove respiratory secretions.
- Severe hemodynamic instability without response to fluids and vasoactive drugs.
- Severe ventricular or supraventricular arrhythmias.
- Life-threatening hypoxemia in patients unable to tolerate NIV.

Hospital discharge and follow-up

The cause, severity, impact, treatment and time course of exacerbations varies from patient to patient and facilities in the community, and healthcare systems, differ from country to country. Accordingly, there are no standards that can be applied to the timing and nature of discharge. However, it is recognized that recurrent exacerbations leading to short-term readmission and increased all-cause mortality are associated with the initial hospitalization for an acute episode of deterioration.284

When features related to re-hospitalization and mortality have been studied, defects in perceived optimal management have been identified including spirometric assessment and arterial blood gas analysis.285 A systematic review has shown that comorbidities, previous exacerbations and hospitalization, and increased length of stay were significant risk factors for 30- and 90-day all-cause readmission after an index hospitalization with an exacerbation of COPD.286 Mortality relates to patient age, the presence of acidotic respiratory failure, the need for ventilatory support and comorbidities including anxiety and depression.287
DISCHARGE CRITERIA AND RECOMMENDATIONS FOR FOLLOW-UP

- Full review of all clinical and laboratory data.
- Check maintenance therapy and understanding.
- Reassess inhaler technique.
- Ensure understanding of withdrawal of acute medications (steroids and/or antibiotics).
- Assess need for continuing any oxygen therapy.
- Provide management plan for comorbidities and follow-up.
- Ensure follow-up arrangements: early follow-up < 4 weeks, and late follow-up < 12 weeks as indicated.
- All clinical or investigational abnormalities have been identified.

1 – 4 WEEKS FOLLOW-UP

- Evaluate ability to cope in his/her usual environment.
- Review and understanding treatment regimen.
- Reassessment of inhaler techniques.
- Reassess need for long-term oxygen.
- Document the capacity to do physical activity and consider patient eligibility to be enrolled in pulmonary rehabilitation.
- Document symptoms: CAT or mMRC.
- Determine status of comorbidities.

12 – 16 WEEKS FOLLOW-UP

- Evaluate ability to cope in his/her usual environment.
- Review understanding treatment regimen
- Reassessment of inhaler techniques.
- Reassess need for long-term oxygen.
- Document the capacity to do physical activity and activities of daily living.
- Measure spirometry: FEV1.
- Document symptoms: CAT or mMRC.
- Determine status of comorbidities.
Prevention of exacerbations

After an acute exacerbation, appropriate measures for prevention of further exacerbations should be initiated (see Table).

Based on findings from observational studies in various countries\textsuperscript{288-291} there was a major decrease in hospital admissions for COPD exacerbations during the COVID-19 epidemic. It was hypothesized that this phenomenon may be a consequence of shielding measures (e.g., wearing masks, avoiding social contact, regular hand washing etc). An alternative explanation is that patients may not have been seeking medical assistance during an exacerbation due to concern about becoming infected with the SARS-CoV-2 virus. If this was the case, then a corresponding increase in COPD related mortality would be expected. However, two major studies from the US and the UK\textsuperscript{288,292} did not report increased COPD associated mortality during the pandemic. Accordingly, shielding measures could be considered during the winter months (on top of established pharmacological and non-pharmacological measures) in patients at risk of exacerbation.

<table>
<thead>
<tr>
<th>INTERVENTION CLASS</th>
<th>INTERVENTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchodilators</td>
<td>LABAs</td>
</tr>
<tr>
<td></td>
<td>LAMAs</td>
</tr>
<tr>
<td></td>
<td>LABA + LAMA</td>
</tr>
<tr>
<td>Corticosteroid-containing regimens</td>
<td>LABA + ICS</td>
</tr>
<tr>
<td></td>
<td>LABA + LAMA + ICS</td>
</tr>
<tr>
<td>Anti-inflammatory (non-steroid)</td>
<td>Roflumilast</td>
</tr>
<tr>
<td>Anti-infectives</td>
<td>Vaccines</td>
</tr>
<tr>
<td></td>
<td>Long Term Macrolides</td>
</tr>
<tr>
<td>Mucoregulators</td>
<td>N-acetylcysteine</td>
</tr>
<tr>
<td></td>
<td>Carbocysteine</td>
</tr>
<tr>
<td></td>
<td>Erdosteine</td>
</tr>
<tr>
<td>Various others</td>
<td>Smoking Cessation</td>
</tr>
<tr>
<td></td>
<td>Rehabilitation</td>
</tr>
<tr>
<td></td>
<td>Lung Volume Reduction</td>
</tr>
<tr>
<td></td>
<td>Vitamin D</td>
</tr>
<tr>
<td></td>
<td>Shielding measures (e.g., mask wearing, minimizing social contact, frequent hand washing)</td>
</tr>
</tbody>
</table>
COPD AND COMORBIDITIES

OVERALL KEY POINTS:

- COPD often coexists with other diseases (comorbidities) that may have a significant impact on disease course.
- In general, the presence of comorbidities should not alter COPD treatment and comorbidities should be treated per usual standards regardless of the presence of COPD.
- Cardiovascular diseases are common and important comorbidities in COPD.
- Lung cancer is frequently seen in patients with COPD and is a major cause of death.
  - Annual low-dose CT scan (LDCT) is recommended for lung cancer screening in patients with COPD due to smoking according to recommendations for the general population.
  - Annual LDCT is not recommended for lung cancer screening in patients with COPD not due to smoking due to insufficient data to establish benefit over harm.
- Osteoporosis and depression/anxiety are frequent, important comorbidities in COPD, are often under-diagnosed, and are associated with poor health status and prognosis.
- Gastroesophageal reflux (GERD) is associated with an increased risk of exacerbations and poorer health status.
- When COPD is part of a multimorbidity care plan, attention should be directed to ensure simplicity of treatment and to minimize polypharmacy.

COVID-19 AND COPD

OVERALL KEY POINTS:

- Patients with COPD presenting with new or worsening respiratory symptoms, fever, and/or any other symptoms that could be COVID-19 related, even if these are mild, should be tested for possible infection with SARS-CoV-2.
- Patients should keep taking their oral and inhaled respiratory medications for COPD as directed as there is no evidence that COPD medications should be changed during this COVID-19 pandemic.
- During periods of high prevalence of COVID-19 in the community, spirometry should be restricted to patients requiring urgent or essential tests for the diagnosis of COPD, and/or to assess lung function status for interventional procedures or surgery.
- Physical distancing and shielding, or sheltering-in-place, should not lead to social isolation and inactivity. Patients should stay in contact with their friends and families by telecommunication and continue to keep active. They should also ensure they have enough medication.
- Patients should be encouraged to use reputable resources for medical information regarding COVID-19 and its management.
- Guidance for remote (phone/virtual/online) COPD patient follow-up and a printable checklist are provided.
For COPD patients the worry of developing COVID-19 as well as the effects of the pandemic on the basic functions of society and/or social services pertaining to their health imposes additional stressors to their condition. The COVID-19 pandemic has made routine management and diagnosis of COPD more difficult as a result of reductions in face-to-face consultations, difficulties in performing spirometry and limitation in traditional pulmonary rehabilitation and home care programmes. Patients have also faced shortages of medication.  

<table>
<thead>
<tr>
<th>KEY POINTS FOR THE MANAGEMENT OF STABLE COPD DURING COVID-19 PANDEMIC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PROTECTIVE STRATEGIES</strong></td>
</tr>
<tr>
<td>• Follow basic infection control measures</td>
</tr>
<tr>
<td>• Wear a face covering</td>
</tr>
<tr>
<td>• Consider shielding/sheltering-in-place</td>
</tr>
<tr>
<td>• Have the COVID-19 vaccination in line with national recommendations</td>
</tr>
<tr>
<td><strong>INVESTIGATIONS</strong></td>
</tr>
<tr>
<td>• Only essential spirometry</td>
</tr>
<tr>
<td><strong>PHARMACOTHERAPY</strong></td>
</tr>
<tr>
<td>• Ensure adequate supplies of medications</td>
</tr>
<tr>
<td>• Continue unchanged including ICS</td>
</tr>
<tr>
<td><strong>NON-PHARMACOLOGICAL THERAPY</strong></td>
</tr>
<tr>
<td>• Ensure annual influenza vaccination</td>
</tr>
<tr>
<td>• Maintain physical activity</td>
</tr>
</tbody>
</table>
COVID-19 & COPD

COPD patient Not infected

mild COVID-19

Dyspnea & Infiltrates

ARDS

Convalescent COVID

Clinical Features

COPD: Cough, SOB

Mild constitutional symptoms
Fever > 37.5 °C, ↑ SOB
Dry Cough, Fatigue, Diarrhea

ARDS
SIRS/Shock
Cardiac Failure
VTE

Fatigue
SOB
Cough

Abnormal Investigations

ARDS
SOB
Cough

SARS-CoV-2 PCR
CXR/CT, SpO₂
Lymphopenia
Thrombocytopenia
CRP, D-dimer

CXR/CT, SpO₂
Lymphopenia
Thrombocytopenia
Transaminases
D-dimer, PCT

SpO₂
CRP, LDH, IL-6
D-dimer, ferritin
troponin, BNP

PFT
CT Chest

Continue Usual COPD Maintenance Therapy

Possible Interventions

Home exercise
Protective Strategies

Protective Strategies,
COPD Exacerbation Therapy
Low intensity exercise
Therapeutic Trials

Controlled Oxygen
Systemic Steroids
Remdesivir
Anticoagulation
Therapeutic Trials

NIH HFNT
IMV
Prone positioning
Anticoagulation
Therapeutic Trials

Home exercise
PR

(ARDS, Adult respiratory distress syndrome; BNP, brain natriuretic peptide; CRP, C reactive protein; CT, computed tomography; CXR, chest radiograph; HFNT, high flow nasal therapy; IL-6, interleukin 6; IMV, invasive mechanical ventilation; LDH, lactate dehydrogenase; NIV, non-invasive ventilation; PCT, procalcitonin; PFT, pulmonary function tests; PR, pulmonary rehabilitation; SOB, Shortness of breath; SpO₂, peripheral oxygen saturation; VTE, venous thromboembolism)

Reprinted with permission of the American Thoracic Society.
Copyright © 2020 American Thoracic Society. All rights reserved.
Halpin et al. 2020. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The 2020 GOLD Science Committee Report on COVID-19 & COPD. Published Ahead of Print: https://thorax.bmj.com/content/75/suppl_2/1
The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.
REMOTE COPD PATIENT FOLLOW-UP DURING COVID-19 PANDEMIC RESTRICTIONS

During the COVID-19 pandemic, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recognizes that there is a need for developing new approaches to interact with COPD patients. Remote consultations are superb tools to minimize the risk of transmitting coronavirus and will be necessary for some time. The systems put in place to facilitate remote consultations should also help increase the efficiency and capacity of the health care system into the future.294 Please see the full GOLD 2021 report for guidance about how i) to prepare for the remote visit; ii) to set up the visit agenda with the patient; and iii) a standardized checklist for follow-up of COPD patients whether in-person, by phone or in a virtual/online setting.

REFERENCES

The full list of references for this pocket guide can be found online at: www.goldcopd.org/pocketguidereferences.